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Preface 
Recombinant D N A methods are powerful, revolutionary techniques 
for at least two reasons. First, they allow the isolation of single genes in 
large amounts from a pool of thousands or millions of genes. Second, the 
isolated genes from any source or their regulatory regions can be modified 
at wil l and reintroduced into a wide variety of cells by transformation. 
The cells expressing the introduced gene can be measured at the R N A 
level or protein level. These advantages allow us to solve complex biolog-
ical problems, including medical and genetic problems, and to gain deeper 
understandings at the molecular level. In addition, new recombinant 
D N A methods are essential tools in the production of novel or better 
products in the areas of health, agriculture, and industry. 
The new Volumes 216, 217, and 218 supplement Volumes 153, 154, 
and 155 of Methods in Enzymology. During the past few years, many new 
or improved recombinant D N A methods have appeared, and a number of 
them are included in these new volumes. Volume 216 covers methods 
related to isolation and detection of D N A and RNA, enzymes for manipu-
lating DNA, reporter genes, and new vectors for cloning genes. Volume 
217 includes vectors for expressing cloned genes, mutagenesis, identify-
ing and mapping genes, and methods for transforming animal and plant 
cells. Volume 218 includes methods for sequencing D N A , PCR for ampli-
fying and manipulating D N A , methods for detecting DNA-pro te in inter-
actions, and other useful methods. 
Areas or specific topics covered extensively in the following recent 
volumes of Methods in Enzymology are not included in these three vol-
umes: "Guide to Protein Purification," Volume 182, edited by M . P. 
Deutscher; "Gene Expression Technology," Volume 185, edited by 
D. V. Goeddel; and "Guide to Yeast Genetics and Molecular Bio logy," 
Volume 194, edited by C Guthrie and G. R. Fink. 
R A Y W U 
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[40] Footprinting of DNA-Binding Proteins in Intact Cells 
By P E T E R B . B E C K E R , F A L K W E I H , and G Ü N T H E R S C H Ü T Z 
Introduction 
The molecular analysis of protein factors that regulate important pro-
cesses in the cell nucleus, such as transcription, replication, and recombi-
nation, has intensified over recent years. The mechanism of action of one 
class of protein factors (exemplified by transcription factors) requires their 
specific binding to short D N A sequence modules at regulatory loci in the 
genome.1"3 Powerful techniques such as DNase I footprinting 4 have been 
developed to demonstrate specific binding of purified proteins or compo-
nents of crude nuclear extracts to D N A in vitro. The D N A in these assays 
usually is of low complexity and easily accessible to the protein to be 
studied. Genomic D N A in the nucleus of eukaryotes, however, is of high 
sequence complexity and associated with histones and nonhistone proteins 
to form the hierarchical structures of chromatin. 5 The density of structural 
protein components associated with D N A in the nucleus and its resulting 
highly compacted state raise questions as to whether the proteins that bind 
to naked D N A in vitro wi l l have access to their potential binding sites in 
chromatin. It is of particular interest in this context, whether chromatin 
structure contributes to the mechanisms of regulation by modulating the 
accessibility of factors to their binding sites in response to extracellular 
stimuli. 6 
The development of genomic footprinting enabled the direct visualiza-
tion of specific pro te in-DNA interactions within the living cell . 7 The re-
finement of the indirect end-labeling technique 8 , 9 by Church and Gilbert , 1 0 
along with an improved hybridization protocol and single-nucleotide reso-
lution of stretches of genomic D N A , allows the mapping of highly complex 
genomic D N A . Although originally designed to obtain genomic sequence 
1 N . C. Jones, P. W. Rigby, and Ε. B. Ziff, Genes Dev. 2, 267 (1988). 
2 W. S. Dynan, Cell 58, 1 (1989). 
3 P. J. Mitchell and R. Tjian, Science 245, 371 (1989). 
4 D. J. Galas and A. Schmitz, Nucleic Acids Res. 5, 3157 (1978). 
5 D. S. Pederson and R. T. Simpson, ISI Atlas Sei.: Biochem. 1, 155 (1988). 
6 A. Wolffe, New Biol. 2, 211 (1990). 
7 A. Ephrussi, G. M. Church, S. Tonegawa, and W. Gilbert, Science 227, 134 (1985). 
8 C. Wu, Nature (London) 286, 854 (1980). 
9 S. A. Nedospasov and G. P. Georgiev, Biochem. Biophys. Res. Commun. 92, 532 (1980). 
1 0 G. M. Church and W. Gilbert, Proc. Natl. Acad. Sei. U.S.A. 81, 1991 (1984). 
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information and to map the occurrence of modified nucleotides, 1 0 the 
protocols were immediately applicable for footprinting experiments in the 
context of the entire genome; the direct labeling of a cloned D N A fragment 
used in an in vitro experiment is replaced by indirect end-labeled probing, 
which visualizes the sequence of interest selectively. 7 1 1 
The methods we wil l describe in detail are refinements of the original 
p ro toco l 7 1 0 and have been found to reproducibly yield in vivo footprints 
of high quality from mammalian genomes. The importance of the genomic 
footprinting approach is highlighted in a study 1 2 of a series of ubiquitous 
proteins that interact with sequences upstream of the rat tyrosine amino-
transferase (TAT) gene in vitro. While all factors were present in the nuclei 
of cells whether they did or did not express the T A T gene, productive 
interaction of the proteins with their potential binding sites was observed 
only in the TAT-expressing hepatoma cells. 1 2 Because all binding sites in 
the chromatin of the TAT-expressing cells, but not of the nonexpressing 
cells, are within regions that are hypersensitive to DNase I , these results 
may document an involvement of chromatin components in the determina-
tion of binding site accessibility. Occlusion of proteins from potential 
binding sites in vivo may also be due to CpG methylation in mammalian 
D N A . Binding of a number of transcription factors has been shown to be 
sensitive to modification of CpG residues in their recognition sites. 1 3 , 1 4 
Genomic sequencing can be used to obtain important information about 
the methylation status of CpGs in the nucleus and—in combination with 
in vivo footprinting—their effects on protein interaction. 1 2 , 1 5 Genomic 
footprinting has yielded valuable information about the mechanisms of 
action of well-known transcriptional activator proteins. For example, al-
though the interaction of steroid receptors with their response elements 
in vivo is dependent on the presence of the hormone, 1 6 - 1 8 purified glucocor-
ticoid and progesterone receptors can interact with their binding sites in 
vitro in the absence of hormones. 1 9 , 2 0 Binding of a factor to the metal-
responsive element of the metallothionein promoter was also observed 
1 1 P. B. Becker and G. Schütz, Genet. Eng. 10, 1 (1988). 
1 2 P. B. Becker, S. Ruppert, and G. Schütz, Cell 51, 435 (1987). 
1 3 M. Höller, G. Westin, J. Jirizny, and W. Schaffner, Genes Dev. 2, 1127 (1988). 
1 4 F. Watt and P. L. Molloy, Genes Dev. 2, 1136 (1988). 
1 5 H. P. Saluz, J. Jiricny, and J. P. Jost, Proc. Natl. Acad. Sei. U.S.A. 83, 7167 (1986). 
1 6 P. B. Becker, B. Gloss, W. Schmid, U. Strähle, and G. Schütz, Nature (London) 324, 686 
(1986). 
1 7 J. N . J. Philipsen, B. C. Hennis, and G. AB, Nucleic Acids Res. 16, 9663 (1988). 
1 8 J. Wijnholds, J. N . J. Philipsen, and G. AB, EMBO J. 7, 2757 (1988). 
1 9 T. Willmann and M. Beato, Nature (London) 324, 688 (1986). 
2 0 A. Bailly, C. lePage, M. Rauch, and E. Milgrom, EMBO J. 5, 3235 (1986). 
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only after metal induction. 2 1* 2 2 In contrast, a cAMP-responsive element 
(CRE) located within the tissue-specific enhancer of the T A T gene is 
contacted by protein even in uninduced hepatoma cells, reflecting the 
basal state of protein interaction at this CRE and the basal level of tran-
scription. A detailed genomic footprinting analysis monitoring protein 
interaction at the CRE during cAMP stimulation revealed a transient 
modulation of binding activity correlating with transcriptional induction. 
This led to the conclusion that activation was brought about by a cAMP-
dependent posttranslational modification of the factor that interacts with 
the cAMP response element.2 3*2 4 Protein binding at the serum response 
element in the control region of the c-fos gene is observed before and after 
serum induction. 2 5 In this case protein-protein interactions or posttransla-
tional modifications of the DNA-binding protein may be required for tran-
scriptional activation. 
In summary, genomic footprinting is the method of choice to study (1) 
the biological relevance of prote in-DNA interactions previously estab-
lished in vitro, (2) the binding sites of factors in order to identify potential 
sites for functional analysis, (3) the accessibility of target sites in chroma-
tin, (4) the mechanisms of action of DNA-binding proteins, (5) the action 
of factors that are unstable during purification, and (6) the occurrence of 
CpG methylation at specific sites. 
Principle 
The genomic footprinting methodology can be subdivided into three 
distinct steps: (1) a chemical reaction performed with intact cells to ran-
domly modify nuclear D N A under conditions in which DNA-binding pro-
teins protect their binding sites from the modification; (2) purification and 
single nucleotide resolution of the genomic D N A ; and (3) visualization of 
the actual footprint. We will focus in this section on the strategy that has 
been successfully applied in the studies mentioned above: the use of 
dimethyl sulfate (DMS) as a reagent to chemically modify D N A in vivo 
and the indirect end labeling by hybridization to visualize the footprint. 
An alternative detection method that employs polymerase chain reaction 
2 1 R. D. Andersen, S. J. Taplitz, S. Wong, G. Bristol, B. Larkin, and H. R. Herschman, 
Mol. Cell. Biol. 7, 35 (1987). 
2 2 P. R. Müller, S. J. Salser, and B. Wold, Genes Dev. 2, 412 (1988). 
2 3 F. Weih, A. F. Stewart, M. Boshart, D. Nitsch, and G. Schütz, Genes Dev. 4, 14 (1990). 
2 4 M. Boshart, F. Weih. A. Schmidt, R. Ε. K. Fournier, and G. Schütz, Cell 61, 905 (1990). 
2 5 R. E. Herrera, P. E. Shaw, and A. Nordheim, Nature (London) 340, 68 (1989). 
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(PCR) amplification of the genomic sequences has been described 2 6 - 2 9 and 
wil l be discussed in the final section of this chapter. Alternative routes can 
also be followed to create the footprint on the genomic D N A . Dimethyl 
sulfate has been widely used as a modifying agent for D N A because of its 
small size and hydrophobic character, which enable it to diffuse through 
the cellular and nuclear membranes of intact cells. Various nucleases that 
are often used in in vitro footprinting experiments cannot enter intact cells 
and thus wi l l work only on permeabilized cells or isolated nuclei. I f leaking 
of proteins from nuclei is carefully minimized genomic footprints can also 
be obtained with nucleases. 3 0 - 3 3 
Figure 1 summarizes the technical steps ( l ) - (9) involved in the proce-
dure detailed below. In step (1) of Fig. I a hypothetical prote in-DNA 
interaction in a nucleus is schematized. The binding site for the protein 
contains a guanine (G) residue that is contacted by the protein. Protein 
binding also distorts the nearby D N A structure, symbolized by the adja-
cent G residue. Cells in suspension are treated with DMS, which diffuses 
into the nuclei and methylates the N-7 position of guanines as well as the 
N-3 position of adenines [Fig. 1, step (2)|. The conditions are chosen such 
that a partial methylation of guanine residues is achieved as in the G-
specific sequencing reaction in the Maxam-Gilbert protocol. 3 4 The N-7 
position of guanine is directed toward the major groove of the D N A and 
is frequently contacted by sequence-specific DNA-binding proteins. A 
guanine in the recognition sequence of a protein wi l l be protected from 
methylation in the presence of bound protein and thus methylated at 
reduced frequency as compared with neighboring guanines. Protein bind-
ing to D N A can also result in hyperreactivity of guanines toward DMS. 
This may be caused either by a distortion of the D N A structure in the 
vicinity of a bound protein [see also Fig. 1, step (1)], or by a locally 
increased concentration of DMS due to its trapping in hydrophobic pockets 
of the protein. 3 5 To distinguish DMS reactivity differences of guanines 
caused by protein binding from those due to the microsequence environ-
2 6 P. R. Mueller, and B. Wold, Science 246, 780 (1989). 
2 7 G. P. Pfeiffer, S. Steigerwald, P. R. Mueller, B. Wold, and A. D. Riggs, Science 246, 810 
(1989). 
2 8 Reference deleted in proof. 
2 9 H. P. Saluz and J. P. Jost, Proc. Natl. Acad. Sei. U.S.A. 86, 2602 (1989). 
3 0 K. Zinn and T. Maniatis, Cell 45, 611 (1986). 
3 1 G. Albrecht, B. Devaux, and C. Kedinger, Mol. Cell. Biol. 8, 1534 (1988). 
3 2 R. L . Tanguay, G. P. Pfeifer, and A. D. Riggs, Nucleic Acids Res. 18, 5902 (1990). 
3 3 I . M . Huibregste and D. R. Engelke, Mol. Cell. Biol. 9, 3244 (1989). 
3 4 A. M. Maxam and W. Gilbert, this series, Vol. 65, p. 499. 
3 5 R. T. Ogata and W. Gilbert, Proc. Natl. Acad. Sei. U.S.A. 75, 5851 (1978). 
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In vivo protein-DNA interaction: 
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FIG. 1. A schematic outline of the procedures involved in the in vivo footprinting method-
ology. Steps (1) to (9) are referred to in text. 
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ment, control reactions are carried out in parallel on cells that serve as a 
control for the effect to be observed (e.g., cells that were not treated with 
an inducing agent or cells that do not express the gene under study). I f 
such control cells are not available, protein-free genomic D N A can be 
methylated as a standard. This is, however, not the ideal control because 
it is conceivable that guanine residues in chromatin react differently with 
DMS from those in protein-free D N A in vitro.]b 
After the methylation reaction has been terminated, genomic D N A is 
isolated and then cleaved with a restriction enzyme to create the fragments 
needed for indirect end labeling analysis [Fig. 1, step (3)]. The D N A 
sequence to be analyzed is represented in the genomic D N A pool as a 
family of fragments [Fig. 1, step (4)]. Due to the partial methylation reac-
tion, many fragments wil l carry only one methylated guanine. Most of the 
guanine residues in the nucleus wil l be similar in DMS reactivity and 
fragments with the corresponding methylated G's will be found at approxi-
mately equal frequency. I f guanines were protected from modification, the 
fragment with a methylated G at the corresponding position will be missing 
from the pool. Similarly, a fragment with a DMS-hyperreactive guanine 
will be overrepresentecl in the pool as compared to the D N A from the 
control reaction [Fig. I , step (4), compare left- and right-hand sides]. 
To map the positions and frequency of methylated guanines by indirect 
end labeling, the modification must be converted into a break in the D N A 
backbone [Fig. 1, step (5)]. This is achieved using piperidine, following 
standard sequencing procedures. 3 4 The complex mixture of D N A frag-
ments resulting from restriction enzyme digest and piperidine cleavage 
at sites of methylated guanines is now separated with single-nucleotide 
resolution on an acrylamide gel [Fig. 1, step (6)]. The D N A is then trans-
ferred from the gel onto a nylon membrane to which it is covalently cross-
linked with U V [Fig. 1, step (7)]. From among the vast excess of unrelated 
D N A sequences on the membrane, the fragments of interest are now 
visualized by hybridization of a small D N A probe that abuts the end set 
by the restriction enzyme [see also Fig. 1, step (1)]. The indirect end label 
thus highlights the family of fragments that share the end to which the 
probe hybridizes but differ in the other end, which is determined by the 
position of the methylated guanine [Fig. 1, step (8)]. The labeled bands 
are detected by autoradiography. Each band on the film corresponds to 
the position of a guanine (or a group of unresolved guanines) in the genomic 
D N A . The intensity of each band is correlated with the reactivity of the 
corresponding G residue toward methylation in vivo. Comparison of the 
intensity of each band in the experimental D N A with the one from the 
control reaction allows identification of the guanines within or close to 
DNA-binding sites of proteins in the cell. Both the reduced intensity of a 
X C I F T 0 - 2 B I H T C 
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band [Fig. 1, step (9), protection] or an increased intensity [Fig. 1, step 
(9), enhancement] are indicative of prote in-DNA interaction. 
Figure 2 shows an example of a genomic footprinting experiment. A 
pattern of strong enhancements and weaker protection is caused by protein 
binding to a functional CRE within the cAMP-responsive enhancer of 
the TAT gene in FTO-2B hepatoma cells. CREB protein binding to this 
sequence is neither detected in fibroblast cells, in which the gene is not 
expressed, nor in hepatoma (HTC) cells, in which the gene can no longer 
be induced by cAMP (see Refs. 22 and 23 for further details). 
Procedures 
Each section begins with a list of reagents and materials needed, fol­
lowed by a basic description of the procedure and finally a section with 
additional comments, hints, and background information. High-quality 
chemicals are used throughout the procedures. 
In Vivo Methylation of Cells 
Materials 
Dimethyl sulfate (DMS): Fluka(Ronkonkoma, N Y ) , puriss. p. Α. , stored 
in the dark at 4° under nitrogen; DMS is a potent carcinogenic agent 
and thus all solutions containing DMS as well as used plasticware 
should be inactivated with 5-10 Μ NaOH 
Phosphate-buffered saline (PBS): 140 m M NaCl, 2.5 mM K C l , 8.1 m M 
N a H 2 P 0 4 , 1.5 m M K H 2 P 0 4 , pH 7.5 
Nuclei buffer: 0.3 Μ sucrose, 60 mM K C l , 15 mM NaCl , 60 mM Tris-
HC1 (pH 8.2), 0.5 mM spermidine, 0.15 mM spermine, 0.5 m M ethyl­
ene glycol-bis (ß-aminoethyl ether)-N,N,7V',N'-tetraacetic acid 
(EGTA), 2 m M ethylenediaminetetraacetic acid (EDTA) 
FIG. 2. A typical result of an in vivo footprinting experiment: Protein interaction at a 
cAMP response element within the tissue-specific enhancer of the tyrosine aminotransferase 
(TAT) gene (Ref. 22). The binding of a protein is inferred from prominent enhancements 
(closed boxes) and a weak protection (open box) that correlate with cAMP induction of TAT 
transcription. Control cells, such as a fibroblast cell line (XC) in which the gene is not 
expressed, or HTC hepatoma cells, in which the cAMP induction is impaired, do not show 
protein binding in chromatin. The changes on the upper strand, visible on the autoradiogram, 
are marked on the right-hand side of the sequence, enhancements and protections on the 
lower strand (not shown; see Ref. 22) are indicated to the left of the sequence. The TAT 
CRE sequence is boxed. 
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Nonidet P-40 
Sarkosyl: N-Lauroylsarcosine (Sigma, St. Louis, MO), 20% (w/v) 
Procedure 
Cells are mildly trypsinized and resuspended in 1 ml of the original 
medium at 25° in a 14-ml polypropylene tube. To this 5 μ\ of DMS is added, 
and the reaction is mixed by swirling and incubated for 5 min at 25°. The 
reaction is stopped by the addition of ice-cold PBS to fill the tube and 
chilled on ice. The following steps are performed at 4° without delay. Cells 
are collected by centrifugation in a cooled centrifuge (5 min, 2500 rpm), 
resuspended in 10 ml of cold PBS, and pelleted as before. The cells are 
resuspended in 1.5 ml nuclei buffer and an equal volume of nuclei buffer 
containing 1% (v/v) Nonidet P-40 is added, thoroughly mixed, and incu­
bated on ice for 5 min, during which cell lysis occurs. Nuclei are recovered 
by centrifugation (5 min, 3000 rpm), washed with 5 ml nuclei buffer without 
sucrose or Nonidet P-40, and lysed by suspension in 1 ml 0.5 Μ E D T A 
with vigorous mixing. Sarkosyl and RNase A are added to 0.5% (w/v) and 
250 /Ltg/ml, respectively. After 3 hr of incubation at 37° proteinase Κ is 
added to a final concentration of 250/xg/ml and the incubation is continued 
at 37° overnight. 
The above protocol usually results in a partial methylation of 1 in 500 
base pairs in the genomic D N A . The reaction is dependent on the DMS 
concentration in the nuclei, which in turn is determined by the poor 
solubility of the hydrophobic chemical in water. Increasing the amount of 
DMS or the incubation times does not influence the reaction significantly 
and thus suitable guanine ladders are obtained under a variety of condi­
tions. Once the reaction is stopped the chemical must be removed as 
completely as possible by thorough washes of the cells and nuclei. Traces 
of DMS in the following overnight incubation at 37° wil l continue to react 
with the now protein-free D N A and obscure potential footprints. 
Although the volume of the cell suspension should not be varied, the 
actual cell number is not critical to obtain the desired partial modification. 
Between 4 χ 10 7and2 χ 108 cells have been methylated with satisfactory 
results. Depending on the availability of the cells, it is convenient to 
process a larger number of cells at a time to obtain several hundred 
micrograms of methylated D N A . This D N A can be used for many experi­
ments to visualize proteins interacting with chromatin at different sites. 
Thus the presence of a footprint at one specific site can serve as an 
"internal control ' ' for the results of a new site obtained from the same 
methylated genomic D N A . If , for example, a clear effect of an inducing 
agent is seen at one particular genomic location when methylated D N A s 
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from induced cells and control cells are compared, the absence of such 
effects at another site can be interpreted with confidence. 
Preparing DNA Samples for Electrophoresis 
Materials 
Phenol: Contains 0 .1% (w/v) 8-hydroxyquinoline; equilibrate with 100 
m M Tris-Cl (pH 8.0), 10 m M EDTA 
Phenol-chloroform (1:1): Equilibrate as above 
T E buffer: 10 m M Tris-HCl (pH 8.0), 1 m M EDTA 
Bovine serum albumin (BSA): Nucleic acid enzyme grade, 10 mg/ml 
Piperidine [10 Μ stock, grade I (Sigma)]: Store at 4° in the dark; before 
use dilute freshly to 1 Μ with water 
Loading buffer: 94% (w/v) deionized formamide (Fluka), 0.05% (w/v) 
xylene cyanole, 0.05% (w/v) bromphenol blue, 10 m M EDTA 
Procedure 
The clear and viscous DNA solution after proteinase Κ treatment (see 
above) is diluted by addition of I ml 0.5 Μ EDTA and extracted twice with 
phenol. The high EDTA concentration renders the aqueous phase more 
dense than the organic phase, allowing easy removal of organic phase 
together with the interphase. In the subsequent extraction with phenol-
chloroform, the aqueous phase is the upper phase again. The DNA is 
dialyzed overnight against 3 liters of TE buffer at 4° (one change of buffer). 
To the dialysate add I/10 vol of 3 Μ sodium acetate (pH 7), followed by 
2.5 vol of ethanol. The precipitate is collected by centrifugation, washed 
with 80% ethanol, dried in a desiccator, and finally redissolved in 1 ml of 
TE . The D N A is stored frozen at - 2 0 ° . The concentration of each sample 
should be determined by OD measurement. The D N A is analyzed by 
electrophoresis on a 0.6% (w/v) agarose gel. 
Genomic D N A purified by this procedure is sufficiently clean to be 
easily digested with the restriction endonuclease [see Fig. 1, step (4) 
and below] to create the fixed end for the indirect end labeling. Thirty 
micrograms of each D N A sample is digested with 60 units of restriction 
enzyme overnight at 37° in a volume of 300 μ,Ι. Bovine serum albumin is 
added to 100 μg/ml for stabilization of the enzyme. The reaction is stopped 
by adding E D T A to 10 m M and sodium acetate (pH 7) to 0.3 Μ and the 
D N A is precipitated with 2.5 vol ethanol. After chilling, the D N A is 
collected by centrifugation (10 min, Eppendorf table centrifuge), washed 
with 80% ethanol, and dried in a vacuum concentrator (SpeedVac; Savant, 
Hicksville, N Y ) . Pellets are dissolved in 100 μ\ 1 Μ piperidine and incu-
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bated at 85-90° for 30 min [Fig. 1, step (5)]. After chilling on ice, the 
solution is transferred into a fresh tube and precipitated as above. The 
D N A , which usually is spread over the tube wall as a film, is carefully 
dissolved in 100 μ\ of water and dried for 2 hr in a vacuum concentrator. 
The pellets are dissolved in 20 μ\ of water and dried again for at least 1 hr 
(or overnight). The resulting fluffy pellet is dissolved in 3 μ\ loading buffer. 
Methylated D N A should not be heated above 37° prior to the 
piperidine reaction in order to avoid uncontrolled depurination in the 
neutral buffer conditions. D N A that appears to be larger than 10 kb 
when analyzed on a 0.8% agarose gel wil l be suitable for a genomic 
footprinting experiment. 
Preparing Membranes for Hybridization 
Materials 
GeneScreen membrane (Du Pont/NEN, Boston, M A ) 
Electrophoresis buffer (TBE, pH 8.8) (10 χ stock solution): 162 g Tris 
base, 27.5 g boric acid, 9.5 g Na 2 EDTA · 2H 2 0/ l i ter 
Ashless hardened paper (Cat. No. 103 00187; Schleicher & Schull) 
Blotting buffer (0.5 x TBE, pH 8.4) (10x stock solution): 109 g Tris 
base, 55 g boric acid, 9.3 g Na 2 EDTA · 2H 2 0/ l i ter . Due to the diffusion 
of urea from the gel into the blotting buffer, the buffer must be changed 
before every use 
Procedure 
The piperidine-treated genomic D N A is now separated on a denaturing 
Polyacrylamide sequencing gel [Fig. I , step (6)]. We routinely run wide 
gels (30 x 35 cm), which differ from common sequencing gels in their 
thickness (1 mm) and the cross-linking ratio (acrylamide : bisacrylamide, 
39 : 1). Prior to pouring of the gel both glass plates must be freshly silicon­
ized to facilitate the later blotting of the gel. Gel and electrophoresis buffer 
is T B E , pH 8.8. The gel is prerun at a constant 900 V for about 3 hr, until 
the current stabilizes [or, for convenience, overnight (—12 hr) at 220-250 
V ] , followed by 30 min at 900 V. The D N A samples in loading buffer are 
denatured for 3 min at 85-90°, chilled on ice, and loaded on the gel. 
Electrophoresis is carried out at a constant 900 V (under those conditions 
the gel does not heat up) until the desired resolution is achieved. From 
time to time during the run, dye markers are loaded into the slots adjacent 
to the samples to mark the area to be blotted. After the run, the glass 
plates are carefully separated and the gel covered with a sheet of ashless 
hardened paper to which it sticks tightly and thus can be removed from 
the supporting plate [do not use Whatman (Clifton, NJ) 3 M M paper]. 
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The apparatus used for electroblotting is a replica of the Harvard 
Biological Laboratories model detailed in Ref. 10. Its size (38 x 46 χ 20 
cm, holding 20 liters of buffer) accommodates a wide sequencing gel. Two 
spirals of platinum wire at both the bottom and the lid constitute the two 
electrodes. A supportive plastic grid with feet is covered with a spongy 
pad. The gel supported on paper is placed directly on the dry pad and its 
surface wetted with blotting buffer. The GeneScreen membrane, pre wet­
ted in the same buffer, is placed on top of the gel and trapped bubbles 
are squeezed out carefully. The membrane should be marked so that 
identification of the side that is in contact with the gel is possible. A second 
layer of dry spongy pad is directly put on top of the membrane, and another 
plastic grid with feet completes the "sandwich," which is tied together 
with rubber tubings. The sandwich is flipped over (thus blotting will be 
downward) and slowly submerged into the blotting buffer in a slanted 
position. It is important to make sure that no air bubbles are trapped 
underneath the spongy pad, which would cause severe blotting artifacts. 
The electrodes are connected such that the anode is at the bottom of the 
tank (and itself covered by a spongy pad). Thus gas bubbles are not trapped 
in the sandwich. The transfer is performed in the cold room with precooled 
buffer. It is complete after 1 hr of blotting at constant voltage of 90-100 
V (3-4 A ) . The membrane is now air dried on a filter paper and baked in 
a vacuum oven at 80° for 20 min. Next, the side of the membrane that was 
in contact with the gel is irradiated with UV light (254 nm) [Fig. 1, step 
(7)] to cross-link the D N A covalently to the nylon matrix. A variety of 
devices can be used for irradiation, some of which are commercially 
available. We use an inverted transilluminator from which the quartz glass 
panel is removed and irradiation comes from six bulbs at a distance of 20 
cm for 20 sec (5000 μ W / c m 2 ) . The membrane is now ready for hybrid­
ization. 
We advise that the conditions for U V cross-linking be carefully opti­
mized for each individual device used. With GeneScreen membranes opti­
mal hybridization signals are obtained under cross-linking conditions that 
result in the retention of 30-40% of the blotted D N A on the membrane 
after hybridization and wash. Tighter cross-linking adversely affects its 
base-pairing capacity to the D N A probe during hybridization. 
The spongy pads of the blotting device should not be stored in the 
tank under blotting buffer, but rather separately, as it needs to be dry when 
the gel is placed on it for blotting. When the pads are wet, air bubbles 
cannot escape through the meshes when the sandwich is submerged in the 
buffer, thus causing blotting artifacts. 
To identify the genomic sequence unambiguously, sequence standards 
produced wi th cloned D N A should be run alongside the genomic samples. 
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FIG. 3. Probing strategy. The probe abuls the strategic restriction site (R) and partially 
overlaps the genomic region that can be scanned for protein-DNA interaction with good 
resolution (shaded field). See text for details. 
The plasmid standards must be diluted to a concentration that approaches 
the amount of specific sequence in a genomic sample to yield a signal of 
roughly equal intensity following hybridization. A plasmid containing the 
cloned sequence to be analyzed in the genome is cleaved with the restric­
tion enzyme that is also used to cut the genomic D N A and then subjected 
to Maxam-Gilbert sequencing reactions. 3 4 The reaction products after 
piperidine cleavage are diluted into loading buffer (including 100 μg/ml 
sheared salmon sperm DNA) to genome equivalent abundance, taking into 
account the complexity of the genome (3 χ 109 bp for mammals) and the 
absolute amount of processed genomic D N A to be loaded on the gel (30 
μg). Thus for a plasmid of 3 kb size, 30 pg of DNA equals one genome 
equivalent. Thirty picograms is applied to the sequencing gel in 3 μΐ of 
loading buffer. Plasmid dilutions can be used to evaluate the sensitivity 
of the analysis and provide useful standards to monitor improvements 
during subsequent experiments. 
Probing Strategy 
To visualize interactions of protein at one particular site in the genome 
the indirect end labeling of genomic fragments, constituting the guanine 
sequence ladder, must be achieved. The probing strategy, that is, the 
selection of the "strategic" restriction site in the vicinity of the sequences 
under study as well as the D N A probe itself, deserves some consideration 
(see Fig. 3). Under the stringent conditions of UV cross-linking and hybrid­
ization described, fragments smaller than 70 nucleotides wil l not yield a 
signal. The Polyacrylamide gel resolves genomic D N A with single-nucleo-
tide resolution for about 200-250 bp beyond the point where the hybridiza­
tion signal is picked up (shaded bar in Fig. 3). Thus the restriction site that 
will become the invariant end should be further than 90 bp away from the 
region of focus, the resulting fragment on cleavage longer than 400 bp. The 
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"strategic" restriction endonuclease should cut genomic D N A reliably, be 
reasonably priced, and not be inhibited by possible methylation of its 
recognition sequence. Ideally, the probe fragment itself should be a single-
copy sequence between 100 and 150 nucleotides long (i.e., short in compar­
ison to the restriction fragment to be labeled, to minimize hybridization 
to fragments that do not have the invariant end), should be of moderate 
GC content (35-55% will work), and should abut the strategic restriction 
site. 
Once a suitable restriction site has been selected it is wise to confirm 
its presence in the genome of the cells used by Southern blotting to rule 
out the existence of a restriction site polymorphism. 
Probe Synthesis 
To obtain a suitable hybridization probe as much 3 2P as possible needs 
to be incorporated into a relative short stretch of nucleic acid. We favor 
single-stranded D N A probes over RNA probes produced by transcription 
with phage polymerases 3 6 because precursor dNTPs of higher specific 
activity than the corresponding NTPs can be obtained and because D N A 
polymerases appear to be more efficient in incorporating nucleotides at 
limiting concentrations. Originally 1 0 the single-stranded DNA probe was 
synthesized by primer extension using single-stranded D N A of Μ13-
derived plasmids into which the short probe sequence were cloned. We 
have described a protocol 1 1 that reproducibly yields high-quality probes 
following this strategy. A number of disadvantages with this procedure, 
such as the necessity to clone the probe fragment in both orientations into 
the Μ13 vector, the difficulty to confine radioactive labeling to insert 
sequences only, and the requirement for a gel purification step, have led 
to the development of a new strategy 3 7 that yields probes of high specific 
activity from either strand with minimal effort. 
Materials 
A l l solutions are prepared with diethyl pyrocarbonate-treated water. 
T3/T7 transcription buffer (5 x stock): 200 m M Tris-HCl (pH 8.0), 250 
m M NaCl, 40 m M MgCU, 10 m M spermidine, 50 m M dithiothreitol 
(DTT) 
NTP mix: ATP, GTP, CTP, and UTP (3.3 m M each); store in aliquots 
at - 2 0 ° 
DNase I buffer (10 x stock): 500 m M Tris-HCl (pH 7.5), 50 m M MgCl , , 
10 m M D T T 
3 6 K. Zinn and T. Maniatis, Cell 45, 611 (1986). 
3 7 F. Weih, A. F. Stewart, and G. Schütz, Nucleic Acids Res. 16, 1628 (1988). 
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FIG. 4. Probe synthesis by reverse transcription of an RNA template. The upper line 
displays the Pvull fragment from the probe plasmid (probe DNA inserted into the polylinker 
of pBluescript). The strategy makes use of the symmetric location of two bacteriophage 
promoters and two "universal" primers that correspond to sequences within the promoters. 
The procedure is described in detail in the text. 
RNase inhibitor: 40 U/μΙ (Stratagene, La Jolla, CA) 
RNase-free DNasc I : 1 U/μΙ (e.g., Promega, Madison, WI) 
RT buffer (5 x ): 250 m M Tris-HCl (pH 8.5; pH 8.3 at 42°), 50 m M MgCl , , 
50 m M DTT, 600 m M KCl 
dGCT mix: 20 m M dGTP/dCTP/dTTP; store in aliquots at - 2 0 ° 
[a- 3 2P] dATP: 5000-6000 Ci/mmol 
A M V reverse transcriptase: Avian myeloblastosis virus reverse tran­
scriptase, 20 U/μΙ (Boehringer Mannheim, Indianapolis, IN) 
Procedure 
Figure 4 illustrates the principle of the probe synthesis. The small 
probe fragment is cloned into pBluescribe/pBluescript (Stratagene) or 
any other vector that contains a multiple cloning site flanked by phage 
promoters on either side. After digestion of the plasmid with Pvull (which 
cuts on either side of the insert in the vector) a phage polymerase is 
used to synthesize a large quantity of R N A containing probe and vector 
sequences up to the Pvull site. A n aliquot of this R N A then serves as a 
template for c D N A synthesis. The RNA derived from transcription with 
T7 polymerase is annealed with the T3 primer and extended by reverse 
transcriptase in the presence of radioactive dATP to yield a highly labeled 
c D N A probe specific for one strand of the genomic D N A (see Fig. 4). 
Correspondingly, a probe for the opposite strand can be derived from the 
same plasmid construct simply by using the T3 polymerase and T7 primer. 
The probe synthesis by reverse transcription of an RNA template has a 
number of advantages over the methods that use M13-derived constructs. 
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First, by making use of the symmetric structure of vectors carrying two 
phage promoters, probe DNAs need only be cloned in one orientation. 
Second, when primers hybridizing close to the insert D N A are employed, 
the labeling of vector sequences is minimized. Third, large quantities of 
RNA can be synthesized with the phage polymerases. This RNA can 
be characterized, accurately quantitated, and then serve as template for 
multiple rounds of actual probe synthesis. Fourth, once the RNA template 
has been synthesized, probe preparation is performed in a short time 
and with minimal exposure to radioactivity. Finally, reverse transcriptase 
incorporates dNTPs at low concentrations efficiently and thus mostly 
full-length products are obtained, even under conditions in which only 
one of the dNTPs is provided as an isotope of the highest specific 
activity. 3 7 
The probe plasmid is cleaved with Pvull and the completeness of the 
digestion verified by agarose gel electrophoresis. Ten micrograms of this 
D N A (5 pmol of plasmid) is incubated with 20 μΐ 5 χ transcription buffer, 
10 μΙ NTP mix, 2.5 μΐ RNase inhibitor (100 U ; Stratagene), 5 μΐ RNA 
polymerase (50 U T3 orT7) in a volume of 100 /xl for 15 min at 37°. Thirteen 
microliters of 10 x DNase I buffer and 20 μΙ of RNase-frce DNase I (20 
U ; Promega) are added and the reaction is incubated for further 15 min at 
37° to degrade the D N A template after transcription. The reaction is 
terminated by phenol and phenol-chloroform (1:1) extraction. The follow­
ing precipitations remove unincorporated nucleotides as well as short 
D N A fragments. A one-tenth volume of 7.5 Μ ammonium acetate and 2.5 
vol of ethanol are added, mixed, and the reaction chilled for 5 min on ice. 
After a 5 min spin, the pellet is resuspended in 50 μΐ water, precipitated 
as above, and washed twice with 80% ethanol. After a short period of 
drying in a speed vacuum concentrator it is dissolved in 20 μΐ water. An 
aliquot can be checked on a RNase-free minigel. The RNA concentration 
is determined by optical density (OD) measurement of a 1/200 dilution at 
260 nm and adjusted to 1 pmol/μΐ. Usually 10-20 pmol transcript is ob­
tained per picomole plasmid D N A . The RNA is stored at - 7 0 ° and can 
be used as template for multiple probe synthesis reactions. 
The following conditions of reverse transcription attempt to achieve 
optimal incorporation of a relatively low amount of isotope into largely 
full-length cDNA. For probe synthesis 250-300 μΟΐ [c*-32P] dATP (50 pmol, 
final concentration 5 μ Μ ) is dried down in a SpeedVac and redissolved in 
4 μΐ of template RNA (4 pmol). The RNA is denatured by incubation at 
70° for 5 min and chilled on ice. To the denatured R N A 2 μΐ of the 
appropriate (T7 or T3) primer (40 pmol; Stratagene), 2 μΐ 5 x RT mix, 0.5 
μΐ dGTC mix (final concentration, 1 mM for each dNTP), 0.5 μΐ RNase 
inhibitor (Stratagene), and 1 μΐ reverse transcriptase are added and the 
584 M E T H O D S F O R D E T E C T I N G DNA—PROTEIN I N T E R A C T I O N [40] 
reaction is incubated for 45 min at 42°. Synthesis is terminated by addition 
of 1 μΙ each of 0.5 Μ EDTA and 20% (w/v) sodium dodecyl sulfate (SDS). 
The template RNA is hydrolyzed by addition of 12 μ\ 0.4 Μ NaOH and 
incubation for 15 min at 70° followed by neutralization with 1 μ\ 1 Μ Tris-
HCl (pH 7.5) and 12 μΙ 0.4 Μ HCl . After the addition of 20 μ% carrier 
tRNA the single-stranded D N A probe is recovered by one selective precip­
itation, as above. The pellet is dried in a SpeedVac and dissolved in 200 
μ\ of TE . Incorporation of isotope can be determined with chromatography 
on polyethylene imine cellulose; the length distribution of the probe D N A 
should be checked on a denaturing Polyacrylamide gel. In general a reac­
tion with a probe fragment (100-150 nucleotides) under the above condi­
tions wil l result in an incorporation of 1-5 x 108 dpm. 
It is advantageous to insert the probe fragment into the vector such 
that much of the polylinker is deleted, thus minimizing the contribution of 
vector sequences to the probe D N A . Should the probe D N A contain a 
Pvull site, Pvull cannot be employed to cleave the plasmid. Alternative 
enzymes should be chosen that produce either blunt or 5' overhang ends 
(such as Rsa \ or Ddel) in order to avoid unspecific initiation of the phage 
polymerases at 3' overhang ends. 
Hybridization 
The visualization of the G-specific pattern of a genomic sequence 
requires that the cDNA probe be able to detect femtogram amounts of 
specific sequences in the context of a 107-fold excess of unrelated D N A in 
a highly specific and sensitive hybridization [Fig. 1, step (8)]. The highest 
sensitivity is needed when working with mammalian genomes, requiring 
exposure times of at least 1 week. The success of an experiment is thus 
largely determined by the ratio of specific hybridization to membrane 
background. The hybridization procedure that was originally introduced 
by Church and Gilbert 1 0 is crucial for achieving this goal. 
Materials 
N a 2 H P 0 4 (0.5 M ) , p H 7.2 (solution is 1 Μ with respect to N a + ) : Dissolve 
89 g N a 2 H P 0 4 · 2 H 2 0 in water, adjust the pH with 85% H 3 P 0 4 , and 
make up to 1 liter with water 
Hybridization buffer: 7% (w/v) SDS [Bio-Rad (Richmond, CA) electro­
phoresis purity reagent], 1% (w/v) BSA (A7906; Sigma), 1 m M E D T A , 
0.25 Μ N a , H P 0 4 (0.5 Μ N a + ) , pH 7.2 
Wash buffer: 20 m M N a 2 H P 0 4 (40 m M Na + ), pH 7.2, I m M E D T A , 1% 
(w/v) SDS; 100 m M NaCl are added for each 5% of reduced GC 
contents of the probe D N A (from 50%) 
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Procedure 
The most reliable results with a favorable signal-to-noise ratio have 
been obtained when using a hybridization incubator that contains rotating 
cylinders made of polypropylene or Plexiglas. The initial experiments in 
our laboratory were performed with an adapted bacterial incubator and 
polypropylene measuring cylinders with silicone stoppers. Sophisticated 
hybridization ovens are now commercially available from a number of 
companies. 
Before each hybridization the cylinders must be cleaned thoroughly 
with detergent and 10 Μ NaOH, followed by extensive rinsing with water. 
The inner surface should not be cleaned mechanically (e.g., with a brush) 
to avoid scratching the surface. The dry GeneScreen membrane after U V 
irradiation is wetted by floating on blotting buffer, rolled up, and trans­
ferred into the hybridization cylinder. The membrane is manipulated with 
a thick pipette until it attaches smoothly to the walls without trapping air 
bubbles. Filling the cylinder with buffer facilitates these manipulations. 
Multiple layers of membrane do not adversely affect signal or background 
hybridization. Excess blotting buffer is poured off and 10-20 ml hybridiza­
tion buffer is added. The cylinder is closed and rotated in the incubator at 
65° for at least 30 min. Meanwhile the radioactive probe D N A (1-5 χ 108 
dpm) is added to 10 ml of hybridization buffer and mixed well. After the 
prehybridization (the length of which is not critical) the hybridization mix 
is exchanged for the one containing the probe and the cylinder is again 
rotated at 65° for 16-24 hr. The solution is then poured off and the mem­
brane is rinsed five times with 100 ml wash buffer at 65° while still in the 
cylinder. The following washes are performed at room temperature in 
large trays on a platform shaker. Hot wash buffer is poured into a tray and 
allowed to cool to 65° before the membrane is submerged. Each wash (1 
liter of wash buffer) takes about 5 min, during which the buffer slowly 
cools down. The membrane is then transferred into a second tray again 
with 1 liter wash buffer at 65°. After eight washes of this kind the mem­
branes are generally clean. The wet membranes are stretched between 
two layers of Saran wrap and exposed to Kodak (Rochester, NY) X A R 
film with Du Pont (Wilmington, DE) Cronex Lightning Plus screen at 
- 7 0 ° , the DNA-bound side being in contact with the film. After a 20-
hr exposure weak signals should be visible that usually allow complete 
evaluation of the experiment with regard to the quality of the D N A samples 
and possible footprinted regions. This first exposure also helps to estimate 
the time finally needed (7-14 days) to obtain publication-quality exposures. 
After a satisfactory exposure is obtained, the membrane can be hybrid­
ized with the probe specific for the complementary strand. To strip the 
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old probe, the membrane is submerged in 1 liter 0.2 Μ NaOH and agitated 
for 15 min at room temperature. After neutralization with two washes in 
100 m M N a 2 H P 0 4 (pH 7.2), 1 m M EDTA the membrane is ready for 
rehybridization. The NaOH treatment of the nylon membrane often re­
duces background as well. With every stripping of the membrane, how­
ever, about 10% of the original signal is lost. 
Under the given experimental conditions only fragments larger than 70 
nucleotides are labeled. We have not determined whether smaller frag­
ments are not retained on the membrane because they are not efficiently 
cross-linked or because the stringency of hybridization and washing does 
not allow smaller fragments to hybridize. 
The extremely sensitive hybridization technique described above can 
be used to detect femtogram amounts of specific genomic sequence. How­
ever, it also detects equally small amounts of plasmid that may contami­
nate one or more of the solutions used to prepare the genomic D N A . 
To avoid such contaminations with, for example, the probe plasmid, we 
recommend a strict separation of solutions used for in vivo footprinting 
experiments (such as buffers, ethanol, and phenol). 
Concluding Remarks 
The procedures described in detail have been used with great success 
in our laboratory as well as in others to obtain information about a large 
number of different prote in-DNA interactions. Among the factors studied 
using this method were proteins binding to GREs, CREs, C A A T boxes, 
CACC boxes, G-strings, octamer motifs, and a variety of other sequence 
modules that have yet to be characterized in more detail. Dimethyl sulfate 
has proved to be an extremely useful reagent, even though it presents a 
certain bias to the study of protein binding. Binding to sites that do not 
contain crucial guanines will go undetected and it is also conceivable that 
some proteins themselves may be methylated by the agent and dissociate 
from their binding site. Besides the agent used to footprint a protein in 
vivo, the success of the experiment wil l be largely determined by the 
occupancy of a given site. Thus it is of great importance that the cell 
population to be analyzed be homogeneous with regard to the protein 
interaction. I f only a fraction of the binding sites in the cell pool is occupied 
by a factor because of asynchrony in cell cycle, variable responsiveness 
to environmental stimuli, mixed cell types, or simply because the factor 
does not bind tightly enough in vivo, no clear footprint will be obtained. 
To establish the significance of a specific effect, it is helpful to use control 
cells that are treated in parallel with the ones under study. 
Even though the methods described yield reliable, satisfying results 
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they should by no means be considered perfect. Without doubt, consider-
able improvements wil l be made in the near future as more investigators 
concentrate their efforts and creativity on further developing the tech-
nique. To overcome the need for exposure times in excess of 1 week, 
linear or polymerase chain reaction (PCR) amplification of genomic se-
quences has been used to create genomic sequence and footprints. 2 6 " 2 9 
Although exposure times can be reduced using these procedures, we feel 
that the need to anneal or ligate different oligonucleotides to genomic 
D N A , with the possibilities of false priming and PCR amplification arti-
facts, are disadvantages. Direct genomic sequencing wil l clearly be the 
method of choice, when less complex genomes (such as Drosophila or 
yeast) are analyzed. We are confident that future improvements wil l also 
result in a considerable shortening of exposure times for mammalian geno-
mic footprinting. The most exciting development in this regard will be the 
substitution of chemiluminescent probes for radioactive labeling. 
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preparation of Drosophila genomic DNA 
for, 497 
preparation of λ DNA from HeLa cDNA 
library for, 497 
principle of method, 494-495 
programs for, 504 
standard, 502 
workup and analysis, 503-506 
2-Cyanoethyl-A/,A/-diisopropylaminophos-
phoramidite, of A/-TFA-6-aminohexan-
l-ol, synthesis of, 143 
Cycle sequencing. See Linear amplification 
sequencing 
Cystic fibrosis mutations, detection of. 
with immobilized probe method, 378 
D 
dATP, a-?5S-labeled, radioactive sequenc­
ing with, 182-183 
DBAUTO (computer program), 185 
DBUTIL (computer program), 185 
Decontamination, by UV, 381-388 
Deletion factory cloning vectors, 305 
Deletion mutagenesis. See also Unidirec­
tional mutagenesis 
oligonucleotide-directed 
clones recovered with different size 
deletions after, 68-69 
Μ13 phage DNA after, agarose gel 
electrophoresis of, 70 
Deoxynucleotides, for use in fluorescence-
based sequencing, composition of 
stock solutions, 166 
Deoxyribonucleotide, concentration of, 
size distribution of randomly selected 
clones as function of, in reverse clon­
ing, 55 
Deoxyribonucleotide 4, preparation of, 84 
Deoxyribonucleotide aS, preparation of, 
84 
Dideoxy/deoxy ratio, determination of, 
248-249 
Dideuxyr.ucleotide 
dye-labeled, protocols for use of, 153 
for fluorescence-based sequencing, 
composition of stock solutions, 166 
labeled, for sampled sequence 
fingerprinting, 246-247 
Dideoxy sequencing 
automated, approaches to, 123 
of dsDNA, protocols for, 17 
Sanger method, 27, 108-109, 122 
solid-phase, of PCR products, 93-103 
solutions and buffers for, 193 
Digoxigenin, oligonucleotide labeling with, 
202-204 
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Digoxigenin-labeled primers, alternatives 
to. 221 
Digoxigenin-labeled sequence patterns 
biotin-labeled patterns and, nonradioac­
tive detection of, combined proto­
cols for, 207-209 
nonradioactive detection of 
with peroxidase-antibody conjugates, 
213,221 
protocol for, 207 
with phosphatase-antibody conju­
gates, 221 
protocol for, 207 
Dioxetane substrates, for alkaline phospha­
tase, chemiluminescent, 190 
Direct polymerase chain reaction, 273, 304 
characterization of recombinant DNA 
by, 368 
products of, sequencing with, 277-278 
of Tn5supF insertions in λ, 268-269, 
272-275 
by Vent DNA polymerase, products of, 
274 
Direct polymerase chain reaction-ampli­
fied DNA, analysis on agarose gel, 
366 
Direct sequencing. See also Solid-phase 
sequencing 
of amplified DNA, 3-4, 13, 15-16 
of Xgtl 1 clones, 233-240 
of heterozygous individuals, 14 
from 5 μΙ of whole blood, PCR for, 529-
530 
by Maxam-Gilbert method, 227-233 
optimization of PCR conditions for, 4 
of PCR-amplified DNA 
applications of, 17 
approaches for, 17 
with λ-exonuclease, 532-534 
of PCR products, 27, 79-92, 107 
from low-melting temperature agarose, 
72-79 
methods for, 72-73 
procedures, 109-110 
producing ssDNA in PCR for, 17-26 
Sanger chain termination method, 
228 
with Taq polymerase, 13, 30 
error rate, 16 
protocol for, 13 
sequencing ladder obtained by, 15 
with T7 DNA polymerase, 12 
sequencing ladder obtained by, 15 
Direct transfer electrophoresis, 187-222. 
See also Nonradioactive sequencing 
apparatus for, 195 
design of, 194-195 
maintenance of, 202 
band shape distortions in, 220 
blurry bands with, 216 
chemicals for, 192-193 
chemiluminescence-detected sequencing 
patterns from, 208-209 
comparison with other electrophoresis 
methods for DNA sequencing, 
214 
constant interband spacing in, range 
determinants for, 216 
elution time as function of fragment 
length in, 219 
enzymes, plasticware, machines for, 
191-192 
gels for 
casting of, 197-202 
by sideways clapping, 199-200 
membrane treatment after electropho­
resis, 201-202 
parameters of 
length, thickness, and thermostat-
ting, 215 
practical aspects of, 215 
theoretical aspects of, 216-220 
sandwich, disassembly of, 202 
setup and electrophoresis, 200-201 
thermostatted, glass plate setup for, 
196-198 
typical running conditions and re­
solved bases, 201 
materials for, 191-194 
principle of, 191 
protocols for, 194-202 
readable range of 
increasing, 219-220 
with longer gels, 216-219 
results of, 211-214 
with thinner gels, 216 
solutions and buffers for, 193-194 
thermal runaway with, 215 
thermostatting design for, 195-
197 
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transfer speed in, determination of, 219— 
220 
Dissociation temperature Td, estimation of, 
379 
DNA 
cosmid, recipes for, 249-251 
denatured, precipitation of, 5 
dilution of, 710 
eukaryotic, amplification of, 711 
extraction method for, 391 
flanking, amplification of 
by inverse PCR, 312 
techniques for, 310 
insert, detection of, location of primers 
for, 365 
manipulations of, buffers, solutions, and 
media for, 427 
plant, isolation of, 707 
plasmid 
large-scale digestion of, 514 
recombinant, identification and analy­
sis of, buffers, solutions, and 
media for, 428 
prokaryotic, amplification of, 711 
purification of, preparation and use of 
silica matrix for, 703-704 
recombinant, PCR characterization of 
direct, 368 
on whole cells, 363-368 
regions with strong secondary structure, 
sequencing of, 13-14 
samples, preparation for electrophoresis 
materials for, 577 
procedure, 577-578 
sources of, for RAPD assay, 706-707 
template 
sequencing of, 33-34 
snap-cooling of, 5 
50- to 100-kilobase, restriction fragment 
maps of, construction of, 651-671 
DNA-binding assay, 615-616 
preparation of labeled DNA probe for, 
615 
DNA-binding proteins 
anchoring PCR-amplified DNA with, 526 
footprinting of, 568-587 
GCN4, 526 
genes encoding, isolation of, with spe­
cific recognition site probes, 551-
567 
construction of expression library for, 
557-558 
materials and reagents for, 557 
methods for, 557-566 
principle of, 552-557 
screening of expression library for, 
558-561 
identification of, 615 
lac repressor, 526 
Xgtl 1 recombinants encoding, detection 
of, with multisite DNA probes, 
562 
selection of PCR products by, 526-
534 
applications, 526 
cloning of regions adjacent to regions 
of known sequence with, 527-
529 
materials and reagents, 527 
methods and results, 527-534 
sequence-specific, 551-552 
clones encoding, 566-567 
isolated by screening λ libraries 
with recognition site DNA 
probes, 554 
isolation of, 552, 556-557 
cloning of, strategy for, 553 
detection of, by Western blotting, 
565-566 
purification of, preparation and use of 
magnetic DNA affinity beads in, 
509 
structural motifs, 566 
and specific target sites, simultaneous 
characterization of, 609-618 
that have been sequenced, 534 
tyrR, 526 




analysis for quantitative discrimina­
tion, 436-439 
bound to individual proteins, mapping 
of, 615-616 
cloning of, from dried agarose gels, 695-
704 
containing HREs, demonstration of 
steroid receptor binding to, tech­
niques for, 536-537 
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from dried agarose 
excision of, 701 
purification of, 700-701 
flanking 1S3Ö, nucleotide sequence of, 
318 
identification of, for cloning, 697-700 
analytical electrophoresis for, 698-
699 
digesting genomic DNA for, 698 
drying gel for, 699 
hybridization/autoradiography for, 
699-700 
preparing and labeling oligonucleotide 
probe for, 697 
preparing radiolabeled marker frag-
ments for, 698 
isolation and labeling of, 543-544 
long, subcloning of 
procedures for, 47-48 
by reverse cloning, 47-58 
purification of 
based on agarose gel electrophoresis, 
513 
by FPLC with Mono Q column, 513 
DNA ligase. See T4 DNA ligase 
DNA markers, RAPD, 704-740 
DNA polymerase, 247. See also Taq DNA 
polymerase; T7 DNA polymerase 
comparison of, 715 
Hot Tub, 274 
thermostable, 706 
Vent, long-distance direct PCR amplifi-
cations by, products of, 274 
DNA-protein complexes, long terminal 
repeat (LTR)-MMTV, cell-specific, 
characterization of, 616-618 
by Southwestern blot, 617 
DNA substrates 
3' end 32P labeling of, 597 
5' end 32P labeling of, 596 
for in situ detection of DNA-metaboliz-
ing enzymes, 592-593 
Dot-blot typing, 370 
reverse, 369-381 
Double-stranded DNA, dideoxy sequenc-
ing of, protocols for, 17 
Double-stranded template, 5 
enzymatic conversion to single-stranded 
template, with T7 gene 6 exonu-
clease, 105, 116, 118 
preparation of, 17 
purification of, by PEG precipitation, 
105, 116-117 
sequencing of, with Taq DNA poly-
merase, 108 
Drosophila 
cross-species PCR on DNA from 
preparation of DNA for, 497 
yeast TBP amino acid sequence 
primers for, 499 
TBP PCR product, derived sequence of, 
compared with yeast TBP, 505 
drPATTY. See Polymerization chain 
reaction (PCR)-aided transcript titra-
tion assay, differential restriction 
dsDNA. See Double-stranded DNA 
dsPATTY. See Polymerization chain 
reaction (PCR)-aided transcript titra-
tion assay, differential-size 
DTE. See Direct transfer electrophoresis 
Dye-labeled oligonucleotide 
re versed-phase Η PLC of, 149 
synthesis of, 143 
Dye-labeled primer 
fluorescent sequencing with, 100-102 
specific primer-directed sequencing with, 
122-153 
spectral characteristics of, 150 
Dye-labeled terminators, fluorescent se­
quencing with, 99-100 
Dye-primer sets 
purification of, 152 
synthesis of, 142-143, 152 
Dye-terminator chemistry, 153 
Dynabeads, 509-511 
analytical purification of transcription 
factor r by, 522-524 
coupling of antibodies to, 643-645 
M-450, 639-640 
M-280 streptavidin, selective coupling of 
biotinylated DNA fragments to, 516 
Ε 
EcoRVRsal 517-bp restriction fragment, 
from pBR322, comparison of G, 
G + A, and A reactions on, 224-225 
Electroblotting, 543 
Electrophoresis. See also Gel electropho­
resis 
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analytical, for identification of fragments 
for cloning, 698-699 
direct transfer, 187-222 
one-dimensional 
procedure, 655 
reagent for, 654 





first dimension, 655-657 
of λ phage DNA, first dimension, 656-
657, 662 
of λ phage DNA restriction fragments, 
657-659, 662-663 
second dimension, 657-659 
EMBL4, Tn5supF insertions in, selecting, 
267-268 
Enzymatic detection 
methods of, common questions, 
220-221 
sequencing with, 189-190 
amount of DNA needed for, 220 
Enzymes 
associated with cell walls, 684 
for chromosome assignment by PCR, 
409 
for cross-species PCR, 495-496 
for direct sequencing of PCR products, 
81 
DNA-metabolizing 
in situ detection of 
by activity gel analysis, 587-609 
after Polyacrylamide gel electropho­
resis, 587-609 
procedure for, 589-591 
temperature conditions, 605 
in situ reactions, 600-601 
conditions for, 592-593 
for magnetic DNA affinity purification, 
511-512 
for PATTY, 425-427 
for reverse transcription of mRNA by 
Taq DNA polymerase, 414 
for sampled sequence fingerprinting, 247, 
255-256 
for in situ detection with activity gels, 
594 
stock solutions, 594-595 
Enzyme-substrate systems, chemilumines-
cent, 190 
Equipment. See also Automated 
sequencers 
for capillary gel electrophoresis, 155-
162 
for cloning from dried agarose gels, 
696 
for cross-species PCR, 495 
for direct transfer electrophoresis, 
195 
design of, 194-195 
maintenance of, 202 
for magnetic DNA affinity purification, 
512 
for Maxam-Gilbert method, 229 
for PATTY, 429 
for PCR on whole cells, 364-366 
for purification of fluorochrome-labeled 
oligonucleotides, 148 
for in situ detection of DNA-metaboliz-
ing enzymes with activity gels. 
594 
Escherichia colt 
competent cells, preparation and storage 
of, 621-627 
Κ12 strains, for transposon-based se­
quencing, 292 
one-step transformation of, 621-627 
bacterial strains transformed by. 625 
efficiency of, 626-627 
effect of chemical components on, 
624 
materials for, 622 
method for, 622-624 
preparation of stock solutions for, 622 
procedure, 623, 626 
development of, 623-624 
reagents for, 622 
preparation of, 622 
transformation and storage solution 
for, preparation of, 622-623 
overexpression of proteins in, 556 
strains 
for γδ and mini-γδ mutagenesis, 295-
296 
for PATTY, 427 
for Tn5 mutagenesis, 296 
for transposon- and PCR-based λ 
sequencing, 264 
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Exometh sequencing, with transposon, 
305 
Exonuclease 
choice of, for direct sequencing of PCR 
products, factors influencing. 90-
92 
sequencing reactions mediated by, 89-
90 
T7 gene 6, conversion of double-
stranded template to single-stranded 
template with, 105, 116, 118 
λ-Exonuclease 
direct sequencing of PCR-amplified 
DNA with, 532-534 
single-stranded DNA generated by, 7 
Expression library 
construction of, 557-558 
cDNA synthesis and cloning for. 557— 
558' 
vectors for. 558 
screening of, 558-561 
binding and wash conditions for, 560-
561 
with nonspecific competitor DNA, 
560 
preparation of protein replica filters 
for, 558-559 
protocols for, 558-559 
with recognition site DNA probe, 559-
560 
Extensins, localization of, 682-683 
F 
Factor IX gene 
Alu 4a polymorphism in, PAMSA of, 
399 
human, amino acid 397 of, oligonu­
cleotides specific for transition at, 
393 
Fast protein liquid chromatography 
(FPLC), with Mono Q column, purifi­
cation of DNA fragments by, 513 
Fingerprinting 
direct, 244-245 




by sampled sequencing, 241-258 
Flexible primer strategy, 23-25 
Fluorescent sequencing, 173 
automated 
of PCR products, 104-121 
materials and reagents for, 110-
111 
troubleshooting, 118-121 
specific primer-directed, 122-153 
deoxy- and dideoxynucleotides for use 
in, composition of stock solutions, 
166 
developments in. 153 
with dye-labeled primers. 100-102 
with dye-labeled terminators, 99-
100 
gel handling for, 183-185 
linear amplification, 179-181 
reverse-primer, 181-182 
Fluorochrome-labeled oligonucleotides 
purification of, 147-148 
apparatus for, 148 
procedure, 148 
reagents for. 148 
synthesis of, 144, 146-147 
procedure, 147 
reagents for, 146-147 
Footprinting, 538 
detection methods for, 570-571 
of DNA-binding protein 
applications, 586 
improvements, 587 
in intact cells, 568-587 
principle of, 570-575 
procedures, 575-586 
hybridization, 584-586 
preparing DNA samples for electro­
phoresis, 577-578 
preparing membranes for hybridiza­
tion, 578-580 
probe synthesis, 581-584 
probing strategy, 580-581 
in vivo methylation of cells, 
575-577 
in vivo 
applications of, 569-570 
procedures in, 572 
results of, typical, 574-575 
Forced cloning, 558 
Frog, skeletal muscle α-tropomyosin, 
cDNA for, direct sequencing of, 37 
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G 
GCN4 binding protein, 526 
recombinant fusion form, production and 
isolation of, 527 
GCN4-polymerase chain reaction, 527 
to clone outside region, strategy for, 528 
products of, 530 
Gedankenexperiments, 217-218 
Gel electrophoresis. See also Agarose gel 
electrophoresis; Polyacrylamide gel 
electrophoresis 
analysis of labeling reaction by, 203-204 
buffers for, 193 
capillary, 154-172 
denaturing 
after drPATTY, 437-439 
after dsPATTY. 439 
of DNA-binding, with extracts of Xgtl 1 
and λΜΒΡ-1 lysogens, 563 
limiting factor. 188 
low-melting temperature, 74-75 
for PCR-based mRNA quantitation, 460-
461 
preparative, for cloning from dried 
agarose gels, 700 
procedure for, 184-185 
protocol, 184-185 
sequencing, in low-melting temperature 
agarose, 77 
solutions for, 184, 193 
Gel retardation assays, 537 
GeneScreen membrane, preparation for 
hybridization 
materials for, 578 
procedure for, 578-580 
Gene walking, 124-125 
targeted, 314 
Genotyping, by determination of allelic 
ratios, 487 
Glass plates 
for direct transfer electrophoresis, 195— 
197 
manual polishing of, 196 
preparation of, 198-199 
setup for thermostatted gels, 196-198 
Glucocorticoid receptors 
activation of, 536 
cytoplasmic, Polyacrylamide gel electro­
phoresis of, two-dimensional, 548-
549 
DNA-binding activity of, observations 
that support, 549-550 
DNA-binding characteristics of, 545-547 
extracts from HeLa S3 cells 
Polyacrylamide gel electrophoresis of, 
541-542 
preparation of, 540-541 
interaction with DNA, 544-545 
Glucose-6-phosphate dehydrogenase 
(G6PD) reverse transcription, by 
AMV reverse transcriptase and Taq 
DNA polymerase, 416-417 
Glutaraldehyde, treatment of BioMag 
particles with, 642 
Glycine DNA, RAPD amplification of, 739 
Glycine-rich protein (GRP), 683 
localization of, 683-684 
mRNAs from, tissue-print localization 
of, 680 
GST-GCN4-coated tubes, 527 
Guanidinium thiocyanate-phenol-chloro-
form extraction method, for purifica­
tion of RNA, 442 
Guessmers, 495, 504, 507 
Η 
Haplotyping 
with double PASA, 398 
with PASA, 388-402 
HeLa cDNA library, λ DNA from, prepa­
ration of, for cross-species PCR, 497 
HeLa S3 cells, glucocorticoid receptor 
extracts from, preparation of, 540-541 
Hepatitis Β virus DNA, serum-isolated, 
sequencing gel analysis of, 83 
Heteroduplex formation, measurement 
with solution hybridization, 446 
Heterozygous individuals, direct sequenc­
ing of, 14 
High-performance liquid chromatography, 
333 
purification of PCR templates by, 105-
106 
re versed-phase, of dye-labeled oligonu­
cleotide, 149 
High-speed sequencing, by capillary gel 
electrophoresis, 154-172 
Hormone response elements (HREs), 536 
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DNA fragments containing, demonstra-
tion of steroid receptors binding to, 
techniques for, 536-537 
Human BEK 
assignment of, by PCR across intron, 
409-410 
PCR amplification of, across intron, 408 
Human chromosome 10, BEK PCR prod-
uct and, presence in hybrid cell lines, 
412 
Human factor IX gene, amino acid 397 of, 
oligonucleotides specific for transition 
at, 393 
Human Genome Initiative, 154 
Human herpesvirus 6 reverse transcrip-
tion, by AMV reverse transcriptase 
and Taq DNA polymerase, 418 
Human immunodeficiency virus 1 DNA, 
amplified, quantification of, by affin-
ity-based hybrid collection, 484 
Hybridization, 584-586 
after drPATTY, 437-439 
buffers, solutions, and media for, 428 
to covalently attached oligonucleotide, 
375-376 
in-gel, for identification of fragments for 
cloning, 699-700 
materials for, 584 
preparation of membranes for, 578-580 
probes 
oligonucleotides 
allele-specific, screening with, 72 
analysis by, 370-372 
sequence-specific, analysis of PCR-
amplified DNA with, 369-381 
RACE products, 352-353 
procedure, 585-586 
in solution, 482 
measurement of heteroduplex forma-
tion with, 446 
modifications, 420 
Hydroxyproline-rich glycoprotein mRNAs, 
tissue-print localization of, 680 
I 
Immobilized probe method. See also 
Reverse dot-blot typing 
choice of probe sequence and length for, 
376-380 
detection with, 376 
of cystic fibrosis mutations, 378 
Inosine, 507 
Insert DNA, location of primers for detec-
tion of, 365 
Internal standards, 475 
PCR-based quantitation of mRNA with, 
446-473 
Inverse polymerase chain reaction, 309, 
311-313 
amplification of flanking DNA by, 312, 
315-317 
applications of, considerations for, 319 
choice of restriction endonucleases for, 
320 
efficiency of, 319-320 
methodology for, considerations in, 317-
321 
optimization of, 321 
specificity of, 320 
In vitro amplified DNA, sequencing of, 3-
16 
In vitro runoff transcription, creation of 
mutant reference RNA by, 433-435 
procedure, 434-435 
Irradiation. See Ultraviolet irradiation 
IS5Ö 
DNA fragment flanking, nucleotide 
sequence of, 318 
from ECOR strain 69, mapping by prob-
ing filter containing ordered array of 
λ clones, 319 
j 
Jumping genes, 258 
Κ 
Klenow enzyme, radioactive sequencing 
with, 182-183 
L 
Label duplexing, 190 
Label multiplexing, 190 
lac repressor, 526 
Large-scale sequencing, 305-306, 328-329 
Ligation-mediated polymerase chain reac­
tion, 313 
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Limiting primer method, 20-21 
applications of, 26 
Linear amplification (cycle) sequencing, 
305 
of cross-over PCR products, autoradio-
graph of, 276 
with fluorescently tagged primers 
procedure for, 180-181 
solutions for, 179-180 
of PCR products, protocol for, 271 
with Taq DNA polymerase, protocol for, 
135-137 
of uncloned PCR fragments, 270-271 
Linker scanning, reverse cloning for, 56-
58 
Long terminal repeat (LTR)-MMTV 
DNA-protein complexes, cell-specific. 
characterization of, 616-618 
by Southwestern blot, 617 
Lysogens, Xgtll and XMBP-l, extracts of. 
gel electrophoresis DNA-binding 
assays with. 563 
Μ 
Magnesium concentration, effect on RAPD 
assay, 712 
Magnetic affinity cell sorting (MACS), 
637-651 
application of, 647-651 
to multidrug-resistant cells, 648-649 
to somatic cell hybrids, 649-650 
to viral diagnostics, 650-651 
cell lines for, 641 
efficiency and specificity of, monitoring, 
647-648 
methods, 640-646 
preparation of cell suspensions for, 646-
647 
preparation of plasmid for, 641 
principle of, 639-640 
protocol for, 645-646 
alternate, with trypsin, 645-646 
reagents for, 640-641 
results of, 646-651 
solutions required for, 645 
Magnetic affinity purification, 508-525 
applications of, 508-509 









strategies for, 517-518 
Magnetic beads. See also Dynabeads 
applications of, 525 
coated with monoclonal antibodies. 
preparation of, 641-645 
coating with monoclonal MRK-16 anti­
body, efficiency of, 644 
construction of, procedure for, 514-516 
coupling of DNA to magnetic beads, 
515-516 
large-scale digestion of plasmid DNA, 
514 
selective biotinylation of DNA, 514-515 
containing yeast tRNA T y r Sup 4-o gene. 
preparation of. 521 
preparation of, 512-515 
primer extension reaction on, 486-487 
purification of sequence-specific DNA-
binding proteins with, 509 
streptavidin-coated 
affinity capture on, 486 
selective coupling of biotinylated DNA 
fragments to, 516 
Mapping. See also Probe mapping; Re­
striction mapping; specific procedure 




of TnSsupF insertions in λ clones, 
272-275 
of TrosupF insertions in λ phage, 
268-269 
with RAPD markers, 725-729 
Southwestern blot. 609-618 
of steroid receptors, 535-551 
o( TnSsupF insertions in λ clones, 267-
268, 272-275 
of transposon insertions, 268-269, 300-
303 
strategies for, 286-290 
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Maxam-Gilbert method, 227-233 
advantages of, 233 
apparatus for, 229 
materials and reagents for, 228-229 
methods for, 229-231 
chemical cleavage, 230-231 
end labeling of primer, 229-230 
PCR amplification, 230 
purification of PCR-amplified prod­
ucts. 230 
principle of. 228 
results of, 231-233 
sequencing gel, autoradiograph of, 232 
sequencing reactions, 231 
solutions for, 229 
Mega base sequences, cloning of. 47 
Messenger RNA, 415 
absolute levels of, determination of 
after drPATTY or dsPATTY, 438-439 
by PATTY, 420-445 
techniques for, 420 
cDNA with unknown 5' ends from, 
amplification by one-way PCR, 321-
.135 
glycine-rich protein, tissue-print localiza­
tion of, 680 
glycoprotein, hydroxyproline-rich, tis­
sue-print localization of, 680 
gravity-responsive, in soybean seedlings, 
tissue-print hybridization detection 
of, 694 
PCR-based quantitation of 
advantages of, 473 
to identify efficiency differences be­
tween endogenous and standard 
molecules, 470-471 
with internal standard, 446-473 
analysis of, 461-473 
methods for, 448-461 
principles of, 448-451 
procedure for, 448 
quantification, 460-461 
with radioactive primers, 466-468 
reverse transcription of, 340 
by Taq DNA polymerase, 413-419 
sequencing of, approaches to, 36 
tissue print localization of, 671-681 
Methylation, of cells, in vivo, 575-577 
Methylation interference assays, 538 
Microtiter methods, for Μ13 clones, 173-
187 
advantages, 187 
data compilation, 185-186 
gel handling, 183-185 
electrophoresis protocol, 184-185 
limitations, 187 
preparation of DNA templates in 96-well 
plates, 174-177 
sequencing reactions, 177-183 
by linear amplification with fluores-
cently tagged primers, 179-181 
by radioactive sequencing with 
[a-35S]dATP and Klenow enzyme, 
182-183 
by reverse-primer sequencing with 
fluorescently tagged primers. 181-
182 
Microtiter plates, 96-well. preparation of 
M13 DNA templates in, 174-177 
Microtitration wells 
affinity capture in, 483 
primer extension reaction in, 486 
Minority point mutations, quantification of, 
487-488 
Mixed oligonucleotide-primed amplification 
of cDNA (MOPAC), 494 
Molecular taxonomy, with RAPD markers, 
738-740 
Molecular weight, determination of, by 
activity gels, 602-603 
Monoclonal antibody 
coupling to BioMag particles, 643 
coupling to Dynabeads, 643-645 
coupling to magnetic particles, reagents 
for, 642 
magnetic beads coated with, preparation 
of, 641-645 
MRK-16, coating magnetic beads with, 
efficiency of, 644 
Mono Q column, FPLC with, purification 
of DNA fragments by, 513 
MOPAC. See Mixed oligonucleotide-
primed amplification of cDNA 
Mouse mammary tumor provirus (MMTV), 
long terminal repeat DNA-protein 
complexes, cell-specific, characteriza­
tion of, 616-618 
Multidrug-resistant cells, isolation of, by 
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magnetic affinity cell sorting, 648-
649 
Multiplex sequencing, with transposon-
carried multiplex tags, 305 
Multisite DNA probes, detection of Xgtl 1 
recombinants encoding DNA-binding 
proteins with, 562 
Mutagenesis 
site-directed, creation of mutant cDNA 
template by, 430-433 
unidirectional, with M13. 58-71 
Mutant cDNA template, creation of, by 
site-directed mutagenesis, 430-433 
Mutant reference RNA, creation of, by in 
vitro runoff transcription, 433-435 




detection of, by PCR amplification of 
specific alleles, 388-402 
minority point, quantification of, 487-
488 
Ν 
Native agarose gel electrophoresis, after 
drPATTY. 436-437 
Nested deletions, 305 
Nitrocellulose filter-binding assays, 537 
Nonradioactive sequencing, 187-222 
advantages of, 190 
of biotin- and digoxigenin-labeled pat­
terns, combined protocols for, 207-
209 
of biotin-labeled patterns 
with phosphatase-antibody conju­
gates, 213 
protocols for, 206-207 
colorimetric, of biotin-labeled patterns, 
protocol for, 206-207 
comparison of biotin and digoxigenin 
systems, 221 
comparison of peroxidase vs phospha­
tase systems, 221 
of digoxigenin-labeled patterns 
with peroxidase-antibody conjugates, 
213, 221 
protocol for, 207 
with phosphatase-antibody conju­
gates, 213, 221 
protocol for, 207 
phosphatase-based, membrane stripping 
after, protocol for, 209 
protocols for, 202-210 
detection of patterns, 205-210 
oligonucleotide labeling with biotin 
and digoxigenin, 202-204 
primer annealing, 204 
sequencing reactions, 204-205 
reproducibility, efficiency, and cost 
effectiveness of, 220-221 
solutions and buffers for. 194 
Northern blot, 446 
N-ras DNA, mutated, quantification of, by 
primer-guided nucleotide incorpora­
tion, 488 
Nuclease protection, 538. See also Foot­
printing 
Nucleotides, for direct sequencing of PCR 
products, 81-84 
Nylon filters 
recovery of positive phage from, 633-
634 
efficiency of, 635 
screening of, 633 
storage of phage libraries on, 627-636 
materials and reagents for, 629-630 
method for, 630-634 





passage of homopolymer tailed cDNA 
through, 325-326 
Oligonucleotide 
for affinity-based collection of PCR 
products, 478-481 
allele-specific, for PASA, 392-394 
aminated, labeling of 
with biotin, 203 
with digoxigenin, 203 
attachment to filters, 373-374 
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covalent, 374-375 
biotinylation of, 202-204, 478-481 
complementary to primer and covalently 
cross-linked to alkaline phospha­
tase, use of, 221 
covalently attached 
detection with, 376 
hybridization to, 375-376 
deletion mutagenesis with 
clones recovered with different size 
deletions after, 68-69 
Μ13 phage DNA after, agarose gel 
electrophoresis of, 70 
for direct sequencing of PCR products, 
81-84 
dissociation temperature Td of, estima­
tion of, 379 
dT-tailed, machine synthesis of, 373 
dye-labeled 
re versed-phase HPLC of, 149 
synthesis of, 143 
end-labeled, Sep-Pak purification of, 89 
end-labeling with [γ- 3 2 ?Ρ]ΑΤΡ, 89 
enzymatic dT tailing of, 373 
fluorochrome-labeled 
purification of, 147-148 
synthesis of, 144, 146-147 
kinasing of, for mutagenesis, 67 
labeling of, 478-481 
with biotin and digoxigenin, 202-204 
analysis by gel electrophoresis and 
Stains-All staining, 203-204 
solutions and buffers for, 193 
mismatches within 2 bases of 3' termi­
nus, specificity of, 394 
for PASA, 392 
for PATTY, 425 
pooling of, in one dot, 380 
primers 
for cross-species PCR, 496 
designing, 497-499 
for RAPD assay, 707 
sequences, 327 
for solid-phase sequencing, 95-96 




screening with, 72 
choice of sequence and length of, for 
reverse dot-blot typing, 376-380 
preparing and labeling, 697 
sequence-specific, analysis of PCR-
amplified DNA with, 369-381 
purification of, Sep-Pak solutions for, 
84 
substrates 
design of, 604-607 
mixed, 605-607 
preparation for in situ detection of 
DNA-metabolizing enzymes, 595-
596 
synthesis of, 478-481 
with addition of 5'-reactive amino 
groups, 374 
for transition at amino acid 397 of hu­
man factor IX gene, 393 
Oligonucleotide cassette-mediated poly­
merase chain reaction, 315 
Oligo walking, solid-phase, 98-99 
Olsen and Eckstein phosphorothioate-
based PCR sequencing method, 82 
Oncogene expression, analysis of, 446-
473 
Oncoquant 
construction of, 456-457 
PCR standard, description of, 454-455 
standard RNA, synthesis, purification, 
and quantification of, 455-457 
Oncoquant I , 473 
construction of, 454-455 
primers, 452-453 
structure of, 450-451 
One-sided polymerase chain reaction, 
36-47, 310-311. See also Thermal 
RACE 
advantages of, 335 
amplification of amplified cDNA by, 
directly from bacterial colonies, 
328 
amplification of homopolymer tailed 
cDNA by, 326-327 
amplification of regions downstream (3') 
of known sequence by, 40 
amplification of regions upstream (5') of 
known sequence by, 42 
amplification of specific cDNA target 
molecule by, 41-42 
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amplification of tailed target cDNA by, 
44-45 
applications of, 37 
cells for, 323 
with large-scale plasmid preparations, 
328-329 
materials for, 39, 322 
methods for, 40-45, 323-329 
modified, 321-335 
precautions, 47 
principle of, 37-39 
reagents for, 39 
results, 329-331 
sensitivity of, 37 
specificity of, 46 
technical difficulties, 332-333 
technique of, 323 
troubleshooting, 45-47 
One-sided polymerase chain reaction-
amplified cDNA, homopolymer tailed 
amplification directly from bacterial 
colonies, 328 
Centricon-100 purification of, 327-328 
subcloning and screening of, 328 
One-way polymerase chain reaction(s). See 
One-sided polymerase chain reac­
tion 
Ρ 
PAMSA. See Polymerase chain reaction 
(PCR) amplification of multiple spe­
cific alleles 
Partial cDNA. See Complementary DNA 
ends 
PASA. See Polymerase chain reaction 
(PCA) amplification of specific alleles 
Patterns, nonradioactive detection of, 205-
210 
PATTY. See Polymerase chain reaction 
(PCR)-aided transcript titration assay 
Peripheral blood monocytes, cloning of 
TCR a- and /3-chain cDNA from, 330-
331 
Peroxidase-antibody conjugates, nonradio­
active detection of digoxigenin-labeled 
sequence patterns with, 213, 221 
protocol for, 207 
Peroxidase-based chemiluminescence, with 
luminol and enhancers, 190 
Phagemid, 234 
Phase disruptions, 80 
Phosphatase, biotinylated, biotin-based 
sequencing with, 190-191, 213 
Phosphatase-antibody conjugates 
nonradioactive detection of biotin-la­
beled sequence patterns with, 213 
nonradioactive detection of digoxigenin-
labeled sequence patterns with, 213, 
221 
protocol for, 207 
Phosphatase-based detections, membrane 
stripping after, protocol for, 209 
Phospholipase A 2 gene, transcription 
initiation sites in, detection of, 37 
Phosphoramidites 
Aminolink 2, 143 
amino linker, synthesis of, 144-145 
biotinylated, 103, 221 
Phosphorothioate-based PCR sequencing 
method, Olsen and Eckstein, 82 
Phosphorothioate-containing PCR frag­
ments, sequencing of, troubleshooting 
guide for, 91 
Phosphorothioate residues, incorporation 
into direct sequencing of PCR prod­
ucts, 85-87 
Pilot activity gels, 608 
Plant tissue 
DNA in, isolation of, 707 
mRNA in, tissue-print localization of, 
671-681 
examples of, 678 
Plaque lifts, 632 
Plasmid 
clones, transposon-based sequencing of, 
279-308 
considerations for, 303-304 
Oncoquant I , 473 
construction of, 454-455 
primers, 452-453 
structure of. 450-451 
for PATTY, 427 
pBE1322, πιΔδ-Ι insertions in, map of, 
286 
pBR322, comparison of G, G + A, and 
A reactions on EcoRl/Rsal 517-bp 
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Plex, myöPLEX insertion in, probe 




pUCl 18, reverse cloning with, strategy 
for, 50-53 






amplification of, 114-116 
procedure, 114-115 
reagents for, 114 
DNA sequencing of. 114-116 
procedure. 115-116 
procedure. 115-116 
reagents for, 114 
in transposon-based sequencing, 259, 
292 
transposon-based sequencing, 259 
Plasmid DNA 
recombinant, identification and analysis 
of, buffers, solutions, and media 
for, 428 
Polyacrylamide activity gel electrophore-
sis, nondenaturing, 597-598 
Polyacrylamide activity gels 
denaturing, components of, 599 
nondenaturing, components of, 598 
Polyacrylamide gel electrophoresis 




in situ detection of DNA-metabolizing 
enzymes after, 587-609 
two-dimensional 
of cytoplasmic glucocorticoid recep-
tors, 548-549 
system for, 588 
6% Polyacrylamide sequencing gel, prepa-
ration of, 130-132 
Poly(A)+ RNA, isolation of, 324 
Poly(A) tail, appending to first-strand 
cDNA products, 348-350 
Poly(dG) cDNA, amplification of, TCR a-
and ß-chain PCR products from, 330 
Poly(dT) tails, probe attachment through, 
373-374 
Polyethylene glycol precipitation, purifica-
tion of double-stranded template by, 
105, 116-117 
Polymerase chain reaction (PCR), 23, 31, 
369-370 
across intron, 404 
assignment of human BEK by, 408-
410 
affinity, sequencing PCR products after, 
strategy for, 531 
agarose gel electrophoresis of, 533 
allele-specific, 388-402 
A/w, 314 
amplification followed by restriction 
digestion, 404-405, 410-411 
amplification of bacteriophage library 
inserts, 336-340 
amplification of multiple specific alleles, 
390 
amplification of 3'-untranslated se-
quences, 404 
amplification of specific alleles, 388-
402 
amplification outside known sequence 
boundaries, 309-321 
methodology for, 310-315 
amplification with biotinylated primers, 
481-482 
applications of, 3, 104 
asymmetric. See Asymmetric poly-
merase chain reaction 
chromosome assignment by, 402-407 
competitive, 421-423 
limitations of, 443-445 
conditions for, 383 
cross-over (biparental). See Cross-over 
polymerase chain reaction 
cross-species, 493-508 
cycling of, 5 
direct, 304 
by AmpliTaq DNA polymerase, prod-
ucts of, 273 
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characterization of recombinant DNA 
by, 368 
optimization of conditions for, 4 
products of, sequencing with, 277-278 
of Jn5supF insertions in λ, 268-269, 
272-275 
by Vent DNA polymerase, products 
of, 274 
for direct sequencing from 5μ,1 of whole 
blood, 529-530 
preparation of blood and GCN4 en­
richment for, 530-532 
DNA target length, effect of UV expo­
sure on, 386 
double-stranded, 19 
on Drosophila DNA, yeast TBP amino 
acid sequence primers for, 499 
effect of primer amount on yield, 22 
efficiency of, as function of cycle num­
ber and amount of template, 485 
exonuclease-mediated, 89-90 
flexible primer strategy, 23-25 
GCN4-enriched, 527 
to clone outside region, strategy for, 
528 
products from, 530 
with internal standards, 475 
quantitation of mRNA with, 446-473 
inverse (inverted or inside-out). See 
Inverse polymerase chain reac­
tion 
λ sequencing based on, 258-279 
ligation-mediated, 313 
limitations of, 36 
limiting primer method, 20—21 
applications of, 26 
linear, applications of, 26 
for Maxam-Gilbert sequencing, 230 
methods, 391-392 
modifications, 36-37 
mRNA quantitation based on, 446-473 
nonspecific, 356 
oligonucleotide cassette-mediated, 315 
Oncoquant standard, description of, 
454-455 
with one biotinylated primer, 73 
one-sided or one-way (anchored), 36-47, 
310-311. See also Thermal RACE 
modified, 321-335 
optimal conditions, determination of, 85 
for PATTY, 435-436 
primers 
5' biotinylated, synthesis of, 372-373 
blocking, 6 
pairs, choice of, 85 
radioactive, quantification of mRNA 
with, 466-468 
removal of, 19 
specificity and compatibility of, 85 
problems with, 356 
quantitative, 420-422 
reagents, decontamination of, by UV, 
381-388 
requirements, 321 
reverse transcription of mRNA by Taq 
DNA polymerase followed by, 413-
419 
and sequencing, coupled methods, 105-
109 
single-sided or anchored. See Thermal 
RACE 
and solid-phase sequencing, 94, 96-97 
specificity of, 4 
standard 
and DNA sequencing, 116-118 
methods for, 109-110 
procedure for, 116-117 
standard reactions, for mRNA quantita­
tion, 459-460 
synthesis of ssDNA from, 17-26 
thermal cycling program, typical, 88 
of Tn5supF insertions in λ, 268-269 
touchdown, 495, 500-501, 506-507 
programs for, 502-503 
trial, 85 
vectorette (bubble), 313-314 
on whole cells, 363 
characterization of recombinant DNA 
by, 363-368 
equipment for, 364-366 
reagents for, 364-366 
Polymerase chain reaction (PCR)-aided 
template titration assay, 445 
Polymerase chain reaction (PCR)-aided 
transcript titration assay (PATTY) 
absolute levels of mRNA by, 420-445 
accuracy of, 442-443 
applications of, 445 
differential restriction, 423-425 
advantages of, 440 
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analysis after, 436-439 
methods for, 430-431 
differential-size, 424-425 
advantages of, 440 
analysis after, 438-439 
methods for, 431-433 
problems, 440-441 
procedure, 432-433 
simplification of, 441-444 
titration system for, 441-444 
efficiency of cDNA synthesis reactions 
by, 445 
enzymes for, 425-427 
equipment for, 429 
gel electrophoresis for, 428-429 
limitations of, 443-445 
materials and reagents for, 425-429 
principle of, 423-425 
analytical, 426-427 
technical, 424 
Polymerase chain reaction (PCR) amplifi­
cation of multiple specific alleles 
(PAMSA), 390, 397-400 
of Alu 4a polymorphism, 399 
applications of, 400 
disadvantages of, 397-398 
Polymerase chain reaction (PCR) amplifi­
cation of specific alleles (PASA), 388-
402 
advantages of, 402 
applications of, 389, 402 
carrier testing by, 393 
double, 389, 391, 396-397 
haplotyping six unrelated individuals 
with, 398 
generality of, 395-396 
methods, 392-396 
adjunct, 391-392 
oligonucleotides for, 392 
allele-specific, 392-394 
optimization and troubleshooting, 400-
402 
principle of, 389 
screening of populations for, 394-395 
specificity of 
effects of allele concentration on, 
395 
increasing, 400-402 
Polymerase chain reaction-amplified DNA 
analysis with sequence-specific oligonu­
cleotide hybridization probes, 369-
381 
anchoring with DNA-binding proteins, 
526 
fragments, 20 
purification of, 270-271 
by PEG precipitation, 116 
sequencing of, 3-16, 21-23 
direct 
applications of, 17 
approaches for, 17 
generation of sequencing template 
for, 3-4 
with λ-exonuclease, 532-534 
by Maxam-Gilbert method, 227-233 
methods, 227-228 
with Taq polymerase, protocol for, 13 
transcript, 228 
single-stranded, sample sequencing 
ladders from, 24-25 
Polymerase chain reaction clones, se­
quencing of, 79-80 
Polymerase chain reaction fragments 
cloned, sequence obtained from, confir­
mation of, 47 
phosphorothioate-containing, sequencing 
of, troubleshooting guide for, 91 
uncloned, linear amplification sequenc­
ing of, 270-271 
Polymerase chain reaction-generated 
DNA, cloning of, 357-362 
materials and methods for, 358-360 
Polymerase chain reaction-mediated 
recombinants, production of, 80 
Polymerase chain reaction products 
absent, 356 
accumulation of, during asymmetric 
PCR, 10-11 
agarose gel analysis of, 500 
agarose gel electrophoresis of, 339 
analysis of, during RACE protocol, 350-
351 
artifact, 16 
asymmetric, sequencing of, trouble­
shooting, 119-121 
concatamerization of, with T4 DNA 
ligase, 357-358, 361-362 
cycle sequencing of, protocol for, 271 
detection of 
with labeled probe, 482-485 
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by primer-guided nucleotide incorpo­
ration, 485-487 
from different primers and RNA 
sources, 461-464 
from direct PCR by AmpliTaq DNA 
polymerase, 273 
from direct PCR by Vent DNA poly­
merase, 273 
double-stranded, producing ssDNA 
from, methods for, 25-26 
efficiency of, 474-475 
electrophoretic separation of, 4 




prematurely terminated, 80 
purification of. 25, 230 
quantification of, 474 
by affinity-based collection, 474-492 
oligonucleotides for, 479 
by affinity-based hybrid collection. 
476, 482-485 
after detection with labeled probe, 
483-485 
by primer-guided nucleotide incorpo­
ration, 477, 485-487 
screening of 
with allele-specific oligonucleotide 
probe hybridization, 72 
by restriction enzyme digestion, 72 
techniques for, 72 
selection of, by DNA-binding proteins, 
526-534 
sequencing of, 26-35 
after affinity PCR, strategy for, 531 
automated fluorescent, 104-121 
direct, 27, 79-92, 107 
advantages of, 79-80 
amplification reactions, 87 
determination of optimal PCR con­
ditions for, 85 
end labeling with [γ- 3 2Ρ]ΑΤΡ and 
purification of oligonucleotide 
for, 89 
enzymes for, 81 
exonuclease for, factors influencing 
choice, 90-92 
exonuclease-mediated sequencing 
reactions in, 89-90 
experimental, 81-84 
incorporation of phosphorothioate 
residues into, 85-87 
from low-melting temperature 
agarose, 72-79 
materials for, 81 
methods, 72-73, 85-90, 105 
nucleotides and oligonucleotides for, 
81-84 
oligonucleotide Sep-Pak purification 
solutions for, 84 
Olsen and Eckstein phos-
phorothioate-based method, 82 
overview, 80-81 
primer pairs for, choice of, 85 
procedures, 109-110 
reagents for, 84, 116 
reproducibility of, 90 
scope of, 92 
Sep-Pak purification of end-labeled 
oligonucleotide for, 89 
strategies for, 116 
trial PCRs for, 85 
typical PCR thermal cycling pro­
gram, 88 
errors in, 14-16 
experimental results, 34-35 
materials for, 31-34 
methods, 28-34, 105, 107-108 
principle of, 30-31 
solid-phase dideoxy procedure, 93-
103 
standards for, 30 
with T7 DNA polymerase, 107-108 
third-primer method, 28-30 
troubleshooting, 118-121 
sequencing with, 277-278 
smeared, from bottom of gel to loading 
well, 356 
Southern blot analysis of, 339 
subcloned, sequencing of, 228 
subcloning of, 27 
Polymerase chain reaction template 
asymmetric, sequencing of, by T7 DNA 
polymerase and Taq DNA poly­
merase, comparison of ladders, 15 
DNA 
sequencing of, 33-34 
snap-cooling of, 5, 17 
double-stranded, 5 
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conversion to single-stranded tem­
plate, with T7 gene 6 exonu-
clease, 105, 116, 118 
preparation of, 17 
purification of, by PEG precipitation, 
105, 116-117 
sequencing of, with Taq DNA poly­
merase, 108 
inappropriate, 356 
preparation of, 31-33 
purification of 
by agarose gel electrophoresis or 
HPLC, 105-106 
procedures for, 28-29 
sequencing of, applications of, 121 
single-stranded, 6-12, 17 
generation of, 17-18, 29-30 
from single-stranded template, with 
T7 gene 6 exonuclease, 105, 
116, 118 
Polymorphisms, detection of, by PCR 
amplification of specific alleles, 388-
402 
Polysiyrcnc micropariicles, avidin-coatcd, 
affinity capture on, 482-483 
Population genetics, with RAPD markers, 
738 
Population screening, for PASA, 394-
395 
Potassium tetrachloropalladate(Il) 
cleavage of DNA at adenine with, 222-
223 
enhanced specific depurination of A >^ G 
by, at pH 2.0, mechanism of, 226-
227 
Primer 
amount of, effect on yield, 22 
annealing, 51 
based on yeast TBP amino acid se­
quence, for PCR on Drosophila 
DNA, 499 
biotinylated, 103 
alternatives to, 221 
amplification with, 481-482 
phosphoramidites, 103 
5' biotinylated, synthesis of, 372-373 
blocking, 6 
for cross-species PCR, 495 
for detection of insert DNA, location of, 
365 
digoxigenin-labeled, alternatives to, 221 
dye-labeled 
fluorescent sequencing with, 100-102 
specific primer-directed sequencing 
with, 122-153 
spectral characteristics of, 150 
end labeling of, 229-230 
fluorescently tagged 
linear amplification sequencing with, 
179-181 
reverse-primer sequencing with, 181-
182 
guessmers, 495, 504, 507 
insert-specific, sequencing reactions 
with, 140 
length of, effect on RAPD assay, 717 
nucleotide substitutions in, effect on 
RAPD assay, 718 
oligonucleotide, 95-96 
for cross-species PCR, 496 
for RAPD assay, 707 
for transposon- and PCR-based λ 
sequencing, 266 
Oncoquant I , 452-453 
optimal concentrations, titration of, 11 
pairs 
choice of, 85 
use of, in RAPD assay, 722-725 
primer G + C content of, effect on 
RAPD assay, 716 
radioactive, quantification of mRNA 
with, 466-468 
removal of, 19 
sequence of, and RAPD assay, 714-
718 
specific. See also Specific primer-
directed sequencing 
applications of, 124 
constraints on, 152-153 
for filling gaps, 125 
for multiple sequence analysis, 124-
125 
for sequence analysis, 126 
sequences 
compatibility with 373A analysis, 
142 
selection of, 140-142 
specificity and compatibility of, 85 
for synthesis of ssDNA from PCR, 18-
19 
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universal, 124 
sequencing reactions with, 132 
Primer extension, 446 
on magnetic beads, 486-487 
in microtitration wells, 486 
Primer-guided nucleotide incorporation 
assay, 489-490 
principle of, 477 
quantification of mutated N-ras DNA 
by, 488 
quantification of PCR products by, 477, 
485-487 
Primer walking, 280 
from transposon anchor sites, with 
preformed oligomer libraries, 305 
Probe 
antisense, 35S-labeled, tissue-print hy-
bridization with, 672 
heterologous, 679 
from housekeeping gene, 680 
labeled 
detection of PCR products with, 482-
485 
preparation of, 615 
multisite, detection of Xgtl I recombi-
nants encoding DNA-binding pro-
teins with, 562 
oligonucleotide 
hybridization of, analysis by, 370-372 
preparing and labeling, 697 
for reverse dot-blot typing, choice of 
sequence and length of, 376-380 
sequence-specific, analysis of PCR-
amplified DNA with, 369-381 
32P-labeled, tissue-print hybridization 
with, 672 
RACE products, 352-353 
reamplification of RAPD bands for use 
as, 708 
sense, 679 
specific recognition site, 551-567 
synthesis of, 581-584 
materials for, 581-582 
procedure, 582-584 
by reverse transcription of RNA 
template, 582 
for transposon-based sequencing, 283 
Probe mapping, 289-290. See also Immo-
bilized probe method 
with BamHl digestion, 288-289 
of myöPLEX insertion in Plex plasmid, 
291 
of my6PLEX insertion in standard 
cloning vector containing fragment 
cloned at BamHl site, 288-289 
of transposon insertions, 300-303 
protocol for, 301-302 
Probing, strategy for footprinting, 580-581 
Protein 
cell wall, localization of, with tissue-
print Western blot techniques, 682-
688 
DNA-binding 
selection of PCR products by, 526-
534 
sequence-specific, purification of, 
preparation and use of magnetic 
DNA affinity beads in, 509 
DNA fragments bound to, mapping of, 
615-616 
nuclear, preparation of 
procedures for, 613 
solutions for, 611-612 
renaturation of, 542-543 
TATA box-binding, cloning of, by cross-
species PCR, 493-508 
Protein blotting. See also specific proce-
dure 
to evaluate interaction of steroid recep-
tors with DNA, procedures for, 
535-551 
Protein-DNA complexes, specific, charac-
terization of, strategies for, 609-610 
Protein replica filters, preparation of, for 
screening of expression library, 558-
559 
Protooncogene expression, regulation of, 
446 
Pyrimidine dinucleotides, in segments with 
different UV sensitivities, 387 
R 
RACE. See Rapid amplification of cDNA 
ends 
Radioactive sequencing, 97-99 
with [a-35S)dATP and Klenow enzyme, 
182-183 
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Rana temporaria, skeletal muscle α-tropo­
myosin, cDNA for, direct sequencing 
of, 37 
Random amplified polymorphic DNA 
(RAPD) assay 
amplification by 
competition in, 719-721 
of DNA from different soybean culti-
vars, 736-737, 739 
of DNA from different species, 711 
analysis of genetic data from, 708 
with arbitrary primers, classes of se­
quences amplified by, 729 
dilution of DNA and, 710 
of DNA polymerases, comparison of, 
715 
effect of annealing temperature on, 713 
effect of magnesium concentration on, 
712 
effect of nucleotide substitutions in 
primer on, 718 
effect of primer G + C content on, 716 
effect of primer length on, 717 
hybridizations and, 721-722 
materials and reagents for, 706-707 
methods for, 707-708 
for molecular taxonomy, 738-740 
nature of target sites and, 719 
for population genetics, 738 
primer sequence and, 714-718 
principle of, 705-706 
reaction conditions, 709-714 
results of, 709-725 
documentation of, 708 
from single simulation, 735 
samples, mixing of, 720 
standard amplification conditions for, 
707-708 
use of paired primers in, 722-725 
Random amplified polymorphic DNA 
(RAPD) bands, reamplification of, 721 
for use as hybridization probes, 708 
Random amplified polymorphic DNA 
(RAPD) fingerprinting, 722-723 
Random amplified polymorphic DNA 
(RAPD) markers, 704-740 
API la 
corresponding RFLP, map position of, 
728 
genetic mapping with, 726-727 
map position of, 728 
applications of, 725-740 
comparison with RFLPs, 705 
genetic mapping with, 725-729 
multipoint error in, 732-733 
near-isogenic lines and F 2 pool selec­
tion, 734-737 
standard deviations in, 732-734 
statistical aspects of, 730-734 
two-point error in, 732-733 
mapped, use of, in different genetic 
crosses, 737 
Random amplified polymorphic DNA 
(RAPD) pattern, simplification of, by 
prior DNA cleavage with restriction 
enzymes, 722-723 
Rapid amplification of cDNA ends 
(RACE), 310-311 
advantages of, 353-354 
analysis of amplification products dur­
ing, 350-351 
applications of, in cloning. 341 
modifications, 354 
products 
analysis of, 350-353 
cloning of, 351 
sequencing of, 352 
use of, 351-353 
in construction of full-length 
cDNAs, 353 
as hybridization probes, 352— 
353 
thermal, 340-356. See also One-sided 
polymerase chain reaction(s) 
importance of full-length extension of 
5' end in, 349 
troubleshooting, 354-356 
Rapid sequencing, 47 
Ras mutations, analysis of, in three tumor 
cell lines, 377 
Rat liver epithelial (RLE) cells, parental, 




decontamination by UV, 381-388 
Recognition site probes. See also Specific 
recognition site probes 
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screening expression library with, 559-
560 
screening λ libraries with, clones encod­
ing sequence-specific DNA-binding 
proteins isolated by, 554 
Recombinant DNA 
characterization of 
by direct PCR, 368 
by PCR on whole cells, 363-368 
advantages of, 367-368 
materials and reagents for, 364-366 
methods for, 366-367 
principle of method, 363-364 
problems, 367-368 
plasmid, identification and analysis of, 
buffers, solutions, and media for, 
428 
Recombinant DNA-binding proteins 
characterization of, 561-565 
λΜΒΡ-1, Western blot analysis of, 564-
565 
Renaturation buffers, components of, 
600 
Restriction endonuclease 
5'-ambiguous end, 247 
commercially available, 243 
DNA cleavage with, simplification of 
RAPD pattern by, 722, 724 
half-sites, cloning with, 360 
for inverse PCR, choice of, 320 
terminal sites 
cloning from, efficient, 359-360 
PCR-generated DNA containing, 
cloning of, 357-362 
for two-enzyme digestion 2-D electro­
phoresis mapping, 669-670 
Xhol sites, reconstitution by concata-
merization of half-sites, 361 
Restriction endonuclease digestion, 228 
after drPATTY, 436-437 
PCR amplification followed by, 404-405, 
410-411 
screening by, 72 
in solution 
choice of restriction enzyme pairs for, 
654 
procedure, 654 
reagents for, 654 
strategy for, 513-514 
Restriction fragment 
EcoRVRsal 517-bp, from pBR322, com­
parison of G, G + A, and A reac­
tions on, 224-225 
from λ phage DNA 
singly and doubly digested 
molecular sizes of, 660 
relationship between, 666 
two-dimensional pattern of, 662-663 
Restriction fragment length polymorphisms 
(RFLPs), 705 
comparison with RAPDs, 705 
corresponding to RAPD API la, map 
position of, 728 
Restriction fragment mapping, 651-671 
backward order, 652 
forward order, 652 
of λ phage DNA, 662-663 
sequence matrices for, 664-665 
of 50- to 100-kilobase DNA, 651-
671 
two-enzyme digestion 2-D electrophore­
sis procedure 
advantages of, 670 
applications of, 651, 670 
difficulties, 668-669 
enzymes for, 669 
map construction, 663-665 
methods, 654-669 
construction of maps, 663-665 
construction of matrix, 659-663 




restriction enzyme digestion in 
solution, 654 
second dimension electrophoresis, 
657-659 
principle of, 651-653 
requirements for, 669-670 
results of, 665-669 
Restriction mapping 
of ηΐγδ-1, 294 
from IvosupF insertions, purification of 
k::Tn5supF DNA for, 269-270 
of transposon insertions, 300 
Reverse cloning, 47-58 
annealing primer, 51 
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digestion of ssDNA for, 51-53 
experimental rationale, 50-55 
insertion of target DNA into Μ13 origin 
Plasmids for, 50-51 
for linker scanning, 56-58 
materials, 50 
preparation of target DNAs for, 54 
problems, 58 
results, 55-58 
sequenase reactions. 51 
extent of, 54 
strategy, 52-53 
Reverse dot-blot typing, 369-381 
advantages of, 380-381 
choice of probe sequence and length for, 
376-380 
considerations for, 379 
guidelines for, 379 
influence of spacer length on, 380 
methodologies, 372-376 
Reversed-phase high-performance liquid 
chromatography, of dye-labeled 
oligonucleotide. 149 
Reverse-primer sequencing, with fluores-
cenlly tagged primers 
procedure, 181-182 
solutions, 181 
Reverse transcriptases, heat-stable, 345 
Reverse transcription 
to generate cDNA templates, 342-346, 
348 
procedure, 342-344, 348 
of G6PD, by AMV reverse transcriptase 
and Taq DNA polymerase, 416-417 
of HHV-6, by AMV reverse transcrip­
tase and Taq DNA polymerase, 418 
of mRNA, by Taq DNA polymerase, 
413-419 
for PATTY, 435-436 
problems with, 354-355 




endogenous, preparation of, 457-458 
manipulations of, buffers, solutions, and 
media for, 427 
mutant reference, creation of, by in vitro 
runoff transcription, 433-435 
Oncoquant standard, synthesis, purifica­
tion, and quantification of, 455-457 
from PBMCs, preparation of, 331 
poly(A) +, isolation of, 324 
purification of 
guanidinium thiocyanate-phenol-
chloroform extraction method, 
442 
yield, 465-468 
small auxin up-regulated, in gravistimu-
lated soybean seedling, tissue-print 
localization of, 673 
tissue-print hybridization of, 692-693 
RNA gel blot, purpose of, 673 
RNase protection, 446 
Robot workstation, 177 
R0t analysis. 446 
Runoff transcription, in vitro, creation of 
mutant reference RNA by, 433-435 
S 
Sampled sequence fingerprinting, 241-258 
analysis of larger DNAs with, 256 
capture procedure, 245-246 
with Sequenase, 251-253 
determination of dideoxy/deoxy ratio, 
248-249 
direct procedure, 244-245 
key component of, 244 
materials and reagents for, 246-248 
enzymes, 247 
choice of, 255-256 
labeled dideoxynucleotides, 246-247 
streptavidin magnetic particles, 247-
248 
methods for, 248-255 
preparation of cosmid DNA for, 249-
251 
principle of, 242-246 
Sandwich hybridization assays, 475 
Sanger sequencing method, 27, 108-109, 
122, 228 
SCREENR (computer program), 185 
SCREENV (computer program), 185 
Sep-Pak purification 
of end-labeled oligonucleotide, 89 
of oligonucleotides, solutions for, 84 
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Sequenase, capture fingerprinting with, 
251-253 
Sequenase sequencing kit, sequencing 
from low-melting temperature agarose 
with, 75 
Sequence-tagged sites, 257 
Sequencing. See also Direct sequencing; 
Solid-phase sequencing; specific 
method 
instruments for. See Equipment 
requirements for, 189 
Sequencing patterns 
chemiluminescence-detected 
from acrylamide gel, 210-212 
from direct transfer electrophoresis, 
208-209 
nonradioactive detection of, 205-210 
Shotgun sequencing, 47-48, 494 
rate-limiting step, 173 
strategy of, 123-124 
Shuffle clones, 80 
Silica fines, 703 
Silica matrix, preparation and use of, for 
DNA purification, 703-704 
Nal solution for, 703 
washing solution for, 703 
Single-stranded DNA 
digestion of, 51-53 
from double-stranded PCR-amplified 
fragment, 21 
λ exonuclease-generated, 7 
PCR-amplified, sample sequencing 
ladders from, 24-25 
synthesis of 
from double-stranded PCR products, 
methods for, 25-26 
by limiting primer method, 20-21 
in PCR, 17-26 
materials and methods for, 18-23 
method, 19 
organisms, loci, and primers for, 
18-19 
Single-stranded template(s), 6-12, 17 
production of, 29-30 
by enzymatic conversion from double-
stranded template, with T7 gene 6 
exonuclease, 105, 116, 118 
Site-directed mutagenesis, creation of 
mutant cDNA template by, 430-
433 
Skeletal muscle α-tropomyosin 
European frog, cDNA for, direct se­
quencing of, 37 
zebrafish, cDNA for, direct sequencing 
of, 37 
Small auxin up-regulated RNAs (SAURS), 
in gravistimulated soybean seedling, 
tissue-print localization of, 673 
Snap-cooling, of template DNA, 5, 17 
Sodium dodecyl sulfate, removal of, 542-
543 
Sodium dodecyl sulfate-polyacrylamide 
activity gel electrophoresis, 598-600 
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis 
procedure for, 614 




Solid-phase oligo walking, 98-99 
Solid-phase sequencing 
advantages of, 102 
applications of, 103 
dideoxy, of PCR products, 93-103 
fluorescent 
with dye-labeled primers, 100-102 
with dye-labeled terminators, 99-100 
limitations of, 102-103 
Skeletal muscle α-tropomyosin 
oligonucleotide primers for, 95-96 
PCR and, 94, 96-97 
principles of, 93-95 
radioactive, 97-99 
Solid-state sequencing, with biotin, 6 
Solution hybridization, 482 
measurement of heteroduplex formation 
with, 446 
modifications, 420 
Southern blot analysis, 403 
of PCR products, 339 
Southwestern blot mapping, 609-618 
advantages of, 618 
alternative procedures, 614-615 
applications of, 550-551 
buffers for, 539 
characterization of LTR-MMTV DNA-
protein complexes by, 617 
extension of, 618 
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limitations of, 618 
materials for, 611-613 
methods for, 540-544, 613-616 
DNA-binding assay, 615-616 
gel electrophoresis, renaturation, and 
protein blotting, 614-615 
alternative procedures, 614-615 
preparation of nuclear proteins. 613 
principle of, 538-539, 610 
procedure, 611 
protocol for, 540 
reagents for, 539, 611-613 
of steroid receptors, 535-551 
applications of, 550 
blocking reagents for, 547-549 
blotting procedure, 542-544 
eleclroblolting, 543 
filter blocking and DNA binding, 
544 
isolation and labeling of DNA frag-
ments, 543-544 
SDS removal and protein renatura-
tion, 542-543 
Polyacrylamide gel electrophoresis of 
receptor extracts for, 541-542 
preparation of glucocorticoid receptor 




DNA from, RAPD amplification of, 736-
737 
seed, developing of tissue prints on 
nitrocellulose membrane, 686 
seedling 
gravistimulated, tissue-prinl localiza-
tion of small auxin up-regulated 
RNA in, 673 
tissue-print localization of gravity-
responsive mRNAs in, 694 
stem, tissue-print localization of HRGP 
and GRP mRNAs in, 680 
Spacer length, influence on reverse dot-
blot typing, 380 
Specific primer 
applications of, 124 
constraints on, 152-153 
for filling gaps, 125 
for multiple sequence analysis, 124-
125 
for sequence analysis, 126 
sequences 
compatibility with 373A analysis, 142 
selection of, 140-142 
rules for, 140-141 
Specific primer-directed sequencing, 122-
153 
and 373A automated DNA sequencer, 
127 
automated data analysis, 139-140 
electrophoresis for, 137-139 
general principles of, 124-127 
with insert-specific primer, 140 
materials and methods, 127-150 
overview, 127-128 
preparation of template DNA for, 128— 
130 
selection of specific primer sequences 
for, 140-142 
sequencing reactions, 149-150 
Taq DNA polymerase cycle protocol, 
135-137 ' 
Taq DNA polymerase standard protocol, 
133-135 
Specific recognition site probes, 551-567 
applications of, 567 
isolation of genes encoding DNA-binding 
proteins with 
construction of expression library for, 
557- 558 
materials and reagents for, 557 
methods for, 557-566 
principle of, 552-557 
screening of expression library for, 
558- 561 
limitations of, 557-566 
SI protection, 446 
ssDNA. See Single-stranded DNA 
Stains-All staining, analysis of labeling 
reaction by, 203-204 
Steroid receptors 
activation of, 536 
binding to HRE-containing DNA frag-
ments, demonstration techniques 
for, 536-537 
Southwestern blotting of, 535-551 
Strand-separating gels, 6 
Streptavidin 
biotin-based sequencing with, 190-191, 
213, 221 
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magnetic beads 
affinity capture on, 486 
selective coupling of biotinylated 
DNA fragments to, 516 
magnetic particles, 247-248 
Streptavidin-phosphatase conjugates. 
sequencing with, 221 
STSs. See Sequence-tagged sites 
Subcloned polymerase chain reaction 
products, sequencing of, 228 
Subcloning 
to generate overlapping fragments for 
extended sequencing, procedures 
for, 47-48 
reverse cloning procedure, 47-58 
sequential digestion procedures. 48-50 
shotgun procedure, 47-48 
transposon-mediated in vivo deletion 
procedure, 48 
Sucrose gradient shift (zonal sedimenta­
tion) assays. 537-538 
Sun SPARCstations, 185-186 
Τ 
Tailing, 310 
problems with, 355-356 
Taq DNA polymerase. See also AmpliTaq 
DNA polymerase 
reverse transcription by, 413-419 
efficiency of, 419 
enzymes for, 414 
of G6PD, 416-417 
of HHV-6, 418 
materials for, 414-415 
methods for, 415-417 
mRNA for, 415 
reagents for, 414-415 
solutions for, 415 
sequencing with 
cycle protocol, 135-137 
direct, 13, 30 
of amplified DNA 
error rate, 16 
protocol for, 13 
sequencing ladder obtained by, 
15 
of double-stranded template, 108 
standard protocol, 133-135 
TATA-binding protein 
cloning of, 493-494 
by cross-species PCR, 493-508 
yeast, sequence of 
compared with derived sequence of 
Drosophila TBP PCR product. 
505 
primers for PCR on Drosophila DNA 
based on, 499 
T-cell antigen receptor a- and ß-chain 
cDNA, cloning of, from PBMCs, 330-
331 
PCR products, from amplification of 
poly(dG) cDNA. 330 
T4 DNA ligase, concatamerization of PCR 
product with, 357-358, 361-362 
T7 DNA polymerase 
direct sequencing with, 12 
of amplified DNA, sequencing ladder 
obtained by. 15 
modified, accuracy of sequences gener-
ated by, 58 
sequencing of PCR products with, 107— 
108 
Template titration 
PCR-aided assay, 445 
quantification of ß-actin levels by, 465 
problems of efficiency differences, 
addressing, 468-473 
Tenth International Histocompatibility 
Workshop, 322 
Terminal restriction endonuclease recogni-
tion sites 
cloning from, efficient, 359-360 
PCR-generated DNA containing, cloning 
of, 357-362 
Terminators 
dye-labeled, fluorescent sequencing 
with, 99-100 
fluorescent, labeling with, 252 
TFIIIB, purification of, 525 
TFIIIC. See Yeast transcription factor τ 
T7 gene 6 exonuclease, conversion of 
double-stranded template to single-
stranded template with, 105, 116, 118 
Thermal cycler, for transposon- and PCR-
based λ sequencing, 266 
Thermal RACE, 340-356. See also One­
sided polymerase chain reaction 
experimental procedures for, 342-353 
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materials for, 342 
principles of, 341-342 
Thennus aquatic us DNA polymerase. See 
Taq DNA polymerase 
Third-primer method, for sequencing of 
PCR products, 28-30 
Tissue-print hybridization 
for detecting RNA directly, 688-695 
autoradiography procedure. 693-694 
hybridization of RNA to tissue print. 
692-693 
membranes and printing technique for, 
690-691 
methods, 690-694 
preparation of antisense and sense 
RNA probes for, 691-692 
staining procedure, 693 
detection of gravity-responsive mRNAs 
in soybean seedlings with, 694 
localization of HRGP and GRP mRNAs 
in soybean stem by, 680 
for localization of mRNA in plant tissue, 
671-681 
advantages of, 672-673, 680 
applications of, 671-672 
autoradiography and data analysis, 
677-678 
procedures, 678 
reagents for, 678 
controls for, 679-680 
examples of, 678 
preparation of radiolabeled probes for, 
674-676 
procedures, 674, 677 
purpose of, 673 
reagents for, 674, 676-677 
resolution of, 681 
sensitivity of, 680 
suggestions for, 673 
localization of small auxin up-regulated 
RNA in gravistimulated seedling 
soybean by, 673 
localization of a subunit mRNA of ß-
conglycinin by, 679 
preparation of antisense probes for, 691 — 
692 
preparation of radiolabeled probes for, 
674-676 
procedures, 676 
reagents for, 675 
preparation of sense probes for, 691-692 
of RNA, 692-693 
Tissue printing, 672-674 
materials for, 689-690 
principle of, 689 
soybean seed, on nitrocellulose mem-
brane, developing of, 686 
technique for, 690-691 
Tissue-print Western blot techniques, 682-
688 
materials for, 685 
notes and precautions for, 687-688 
principle of, 685 
procedure, 685-687 
Touchdown polymerase chain reaction. 
495, 500-501, 506 
applications of, 506-507 
parameters that can be varied. 501 
programs for. 502-503 
Transcription, in vitro runoff, creation of 
mutant reference RNA by. 433-435 
Transcription factor, yeast 
determining saturation conditions for, 
520 
magnetic DNA affinity purification of, 
508-525 
method, 516-521 
results of experiment, 521-524 
scaled-up experiment, 520-521 
partially purified extract, 516-517 
protein binding of 
finding optimal concentrations of salt 
for, 519-520 
optimalization of conditions for, 517-
521 
protein elution of, finding optimal con-
centrations of salt for, 520 
Transcription factor TFI11B, purification 
of, 525 
Transcription factor τ (TFIIIC) 
ionic strength of, 517 
magnetic DNA affinity purification of, 
509 
by Dynabeads, 522-524 
Transcript sequencing, 7 
of amplified DNA, 228 
Transcript titration assay, PCR-aided, 
absolute levels of mRNA by, 420-445 
Transfection 
methods of, 637 
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transient expression by, optimizing 
efficiency of, 637 
Transformation and storage solution (TSS), 
622 
preparation of. 622-623 
Transient expression 
studies, 638 
by transfection, optimizing efficiency of, 
637 
Transposon 
appropriate for sequencing, 258 
insertions, mapping, 300-303 
strategies for, 286-290 
small derivatives useful for sequencing, 
290-295 
Transposon-based sequencing 
E. coli strains, plasmids, phage, and 
media for, 292-293 
of λ phage, 258-279 
of plasmid clones, 279-308 
considerations for, 303-304 
materials for, 290-296 
methods for. 296-303 
overview of, 303-304 
principles of, 281-290 
of plasmids, 259 
primers and probes for, 283 
Transposon γδ, 280 
insertion sites in cloned DNA, 287 
mutagenesis by, 281-284 
conditions for, 296-299 
E. coli strains for, 295-296 
liquid mating, 297-298 
plate mating, 298-299 
transposition of, randomness of, 285— 
286 
wild-type, 290 
small derivatives useful for sequenc­
ing, 290-294 
Transposon-mediated in vivo deletion 
procedure, 48 
Transposon myö 
insertion in standard cloning vector 
containing fragment cloned at 
BamHl site, probe mapping of, 288— 
289 
plex set of, 260-bp, 294 
Transposon my6-l, 290-294 
insertions in pBE1322, map of, 286 
restriction map of, 294 
Transposon myÖPLEX 
insertion in compatible Plex plasmid. 
probe mapping of, 291 
insertion in standard cloning vector 
containing fragment cloned at 
BamHl site, probe mapping of, 288-
289 
Transposon myöPLEX-l, 290-294 
Transposon nvy6PLEX-3, 290-294 
Transposon my6PLEX-4, 290-294 
Transposon my8PLEX-5, 290-294 
Transposon mini-γδ, mutagenesis by, 281 
E. coli strains for, 295-296 
Transposon mini-Tn5(pfml), 295 
Transposon Tn5, 262, 280 
mutagenesis by, 281-282, 284-285 
conditions for, 299 
E. coli strains and λ phage for, 296 
small derivatives useful for sequencing, 
294-295 
transposition of, randomness of, 285-286 
wild type, 262 
Transposon Tn9, 305 
Transposon JnSlac, 29A 
Transposon Tn/acZ, 294 
Transposon Tn50RF/«c\ 294 
Transposon TnphoA, 295 
Transposon Tn5seql, 294 
Transposon Tn5supFy 262, 294 
insertions in λ clones, 262-264 
frequency of, 271-272 
isolating and mapping 
to select Tn5supF insertions in 
amber mutant phage, 267 
to select Tn5supF insertions in 
nonmutant phage, 267-268 
to transpose Tn5supF to λ phage, 
266-267 
insertions in λ phage 
PCR mapping of, 268-269 
cross-over (biparental) amplification, 
269 
direct amplification, 268-269, 272-
275 
preparation of λ phage for, 268 
restriction mapping and sequencing 
from, purification of k::Tn5supF 
for, 268-269 
sites of, 272 
transposition of, 263 
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Transposon Tn5tacl, 295 
Transposon walking, 315 
N-Trifluoroacetyl-6-aminohexan-l-ol, 
synthesis of, 143 
procedure, 144-145 
reagents for, 144 
N-Trifluoroacetyl-6-aminohexan-l-ol 2-
cyanoethyl-N,N-diisopropylamino-
phosphoramidite, synthesis of 
procedure, 145 
reagents for, 145 
tRNA T y r Sup 4-o gene, yeast, DNA affinity 
beads containing, preparation of, 521 
α-Tropomyosin, skeletal muscle, cDNA 




reagents for, 655 
second enzyme in situ digestion in gel, 
655-657 
of λ phage DNA, first dimension, 656-
657, 662 
of λ phage DNA restriction fragments, 
657-659, 662-663 
Polyacrylamide gel, of cytoplasmic 
glucocorticoid receptors, 548-549 
second dimension, 657-659 
Tyrosine aminotransferase (TAT) gene, 
cAMP response element in tissue-
specific enhancer of, protein interac­
tion at, 574-575 
tyrR, 526 
U 
Ultrafree-MC filter unit, 333 
Ultrafree-MC 30,000 NMWL, 25 
Ultraviolet irradiation 
decontamination by, 381-388 
and amount of contaminating DNA, 
384-385 
of individual PCR reagents, 385 
materials and reagents for, 382-383 
methods for, 383-388 
irradiation of samples and compo­
nents, 383-384 
PCR conditions for, 383-384 
and sequence of contaminating DNA, 
386-387 
and size of contaminating DNA, 385-
386 




on DNA target length in PCR, 386 
pyrimidine dinucleotides in segments 
with different sensitivities to, 387 
Unidirectional mutagenesis, with Ml3, 58-
71 
advantages of, 61-63 
applications of, 59 
basis for, 59 
clones recovered with different size 
deletions after, 68-69 
competent cells for, 64 
enzymes, chemicals, and radiochemicals 
for, 63 
illustrative examples, 69-71 
limitations of, 71 
materials and reagents for, 63-64 
preparation of nested set of deletions 
with fixed end point, 60-61 
principle of, 59-61 
protocol for, 64-69 
cloning target DNA, 65 
hybridization and extension, 67 
kinasing oligonucleotide, 67 
preparation of replicated form of 
M13K11 or M13K11RX DNA, 
64-65 
preparation of template, 65-67 
transformation, 67-69 
transformation of M13 DNA for, 64 
vectors, recombinants, and host strains 
for, 63-64 
Universal primer, 124 
sequencing reactions with, 132 
general considerations, 132 
3'-Untranslated sequences, amplification 
of, 404 
V 
Vector. See also Plasmid 
for construction of cDNA library, 558 
deletion factory, 305 
\gt, PCR amplification of DNA inserts 
clones in, 336 
806 SUBJECT I N D E X 
\ g t l l , 233-234, 558 
λ phage, transposon- and PCR-based 




unidirectional mutagenesis with, 58-71 
M13K11 
construction of, 63 
DNA, replicated form, preparation of, 
64-65 
polylinker region of, nucleotide se­
quence of, 62 
M13K11RX 
construction of, 63 
DNA, replicated form, preparation of, 
64-65 
polylinker region of, nucleotide se­
quence of, 62 
M13mpl9, capillary gel electrophoretic 
analysis of, 171 
recombinant DNA, characterization of, 
by PCR on whole cells. 363-368 
Veclovetlc (bubble) polymerase chain 
reaction(s). 313-314 
Vent DNA polymerase, long-distance 
direct PCR amplifications by, products 
of, 274 




detection of sequence-specific DNA-
binding proteins by, 565-566 
tissue-print techniques, 682-688 
Whole blood, 5μ\ of, direct sequencing 
from, PCR for, 529-530 
Whole cells, PCR on, 363 
characterization of recombinant DNA 
by, 363-368 
advantages of, 367 
cycling protocol for, 367 
problems, 367-368 
equipment for, 364-366 
reagents for, 364-366 
X 
xdap (computer program), 185-186 
Xhol restriction endonuclease sites, recon-
stitution by concatamerization of half-
sites, 361 
Y 
Yeast regulatory proteins, GCN4, 526 
Yeast TATA-binding protein, sequence of 
compared with derived sequence of 
Drosophila TBP PCR product, 505 
primers based on, for PCR on Drosoph­
ila DNA, 499 
Yeast transcription factor τ 
ionic strength of. 517 
magnetic DNA affinity purification of, 
508-525 
Yeast tRNA T y r Sup 4-o gene, DNA affinity 
beads containing, preparation of, 521 
Ζ 
Zebrafish, skeletal muscle α-tropomyosin, 
cDNA for, direct sequencing of, 37 
Zonal sedimentation assays, 537-538 
